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COMORBID SYMPTOM TREATMENT IN PARKINSON’S DISEASE USING NEUROFEEDBACK

JOANNE MCFARLAND O'ROURKE, PH.D.
WESTERN MICHIGAN UNIVERSITY, 2019
The purpose of this research was to determine the impact of neurofeedback (NFB)
on Parkinson’s symptoms that patients identify as priorities. First, a focus group of patients
helped identify priority symptoms, then a pilot study tested protocols resulting from the
focus group, and finally, an intervention study using a single subject design was conducted.
In the focus group, tremor and activity planning were identified as issues affecting
every group member. The pilot study was conducted with three mid-stage Parkinson’s
patients, who received a sensory motor (SM) protocol to address tremor, a SM plus
cognition protocol (SM+Cog) for tremor and planning (cognition), or no protocol. Theta and
high beta were inhibited, while SMR/beta were rewarded in 12 sessions. The chief outcome
measure was overall disability percentage using World Health Organization Disability
Assessment Scale (WHODAS).
Participants who received either protocol reported less disability posttest and onemonth followup. The person in the control group reported increased disability across
measurements. Analysis of pre- and posttest quantitative electroencephalogram (QEEG)
showed posttest reductions in delta, theta, and high beta, as well as increases in beta for
participants in the intervention groups. QEEGs also demonstrated variation in brain
disregulation, even among participants in the same disease stage.

Next, an intervention study was conducted with seven participants with varying
levels of affectedness from the disease. Outcome measures were self-reported tremor using
the Unified Parkinson’s Disease Rating Scale (UPDRS) and cognition using the WHODAS;
and a single protocol that included both the SM+Cog conditions was used in 20 sessions.
Two baseline EEG measures were taken to document pre-intervention status, and a
qualitative component was added to document changes that participants noticed.
For the three participants who were the furthest away from initial diagnosis, tremor
scores improved at posttest, and EEG measures showed desired reductions in theta and
high beta. Tremor improvement was sustained at follow-up for two of these three
participants. Tremor improved per verbal report, but not quantitative score, for an
additional 2 participants. Cognition scores improved at posttest for four of seven
participants and for an additional participant at follow-up. Of the participants who
reported improvement at posttest, cognition scores returned to pretest levels at the onemonth follow-up for three participants and worsened for the fourth, but not back to pretest
levels. Cognition improved per verbal report for one additional participant. Qualitative
reports of improvement during the intervention included motor symptoms of tremor,
walking and balance; cognitive symptoms of memory, focus, word-finding, and holding a
train of thought in spite of tremor; and other symptoms of sleep, restless leg syndrome,
anxiety/agitation, fatigue, and light-headedness upon standing.
Recommendations were: 1) including self-report and more precise, objective
measures and 2) conducting studies to more accurately delineate changes based on pre-

intervention functioning and attempt to capture symptom delay. The study adds to the
evidence that NFB can be a useful therapy in alleviating motor symptoms of Parkinson’s, as
well as cognitive issues, which are not typically addressed with medication.
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Chapter 1. Introduction
Significance
Parkinson Disease (PD) affects an estimated 1 million people in the U.S., is slowly
progressive, and can affect a broad range of functioning for 20 or more years (Kowal, Dall,
& Chakrabarti, Storm & Jain, 2013). In addition to the human cost of PD, economic costs of
medical care and disability were estimated at $14.4 billion annually in 2010 (Parkinson
Disease Foundation, 2016). Functional areas affected may include physical movement
(tremor, balance), emotionality (mood, anxiety), and cognition (memory, planning) (Getz &
Levin, 2017). Research has shown that motor symptoms decline more in the early stages of
the disease than in the later stages (Maetzler, Liepelt, & Berg, 2009). Research has also
shown that the later a person is diagnosed with PD, as well as the comorbid presence of
dementia and psychosis, the more quickly the disease progresses. Recent studies have
linked the use of anti-PD medications with dementia (Gray & Hanlon, 2018; Coupland, Hill,
Dening, Morriss, Moore, & Hippisley-Cox, 2019), underscoring the importance of delaying
medication initiation, reducing dosages to the extent possible, and exploring alternatives to
drug therapy. Conclusions suggest “treatments to prevent or delay the progression of
movement problems, psychosis and dementia in people with Parkinson's disease could
help people live longer” (American Academy of Neurology, 2010).
Neurofeedback (NFB) is one option that has shown promise in slowing the
progression of Parkinson Disease. The brain's electrical activity, shown as brainwaves on
the electroencephalogram (EEG), was hypothesized by Hans Berger beginning in 1924 to
change according to the functional state of the brain while awake, asleep, or in various
1

states of diseases or injury affecting the brain (Wiedemann, 1994; Gruzelier, 2014;
Robbins, 2000).
NFB is a form of biofeedback that regulates the electrical activity of the brain. NFB is
based on operant conditioning, or positive reinforcement of behavior (Strehl, 2014).
Electrodes attached to the head monitor electrical currents produced in the brain, and
subjects watch a computer game. The computer game provides auditory and visual
“rewards” (more beeps, faster movement) when the brain is producing the desired signals
and thus the individual “learns” to modify her or his brainwaves (Davelaar, 2018). This
creates a reinforcement loop that over time helps normalize brain waves and improve
functioning. That is, the brain responds to the positive feedback by producing more of the
desired brain wave, thus regulating the brain and improving functioning (Marzbani,
Marateb, & Mansourian, 2016). NFB is also referred to as EEG biofeedback and
neurotherapy.
The slowly progressive nature of PD combined with the multiple facets of life
affected by the disease, as well as the benefit of early diagnosis and treatment, create the
need for finding ways to alleviate and delay symptoms for as long as possible, with the goal
not only of improving the quality of life (QOL) but extending life.

Theoretical Basis
The purpose of NFB is to adjust brain wave frequencies that have become
disregulated. Frequencies are divided into bands defined as delta, theta, alpha and beta.
Delta (0-4 hertz) production increases when sleeping, theta (4-8 hertz) production is
associated with the state between sleeping and waking or deep meditation, alpha (8-12
hertz) is associated with low activity while awake, and beta (12-36 hertz) is divided
2

between lower bands associated with being alert and higher bands associated with anxiety
and anger. The optimal amplitude – or intensity – of each brain wave frequency (i.e., delta,
theta, and so on) at each site of the brain is necessary for peak functioning. Studies have
shown particular types of disregulation in PD and that NFB may help address this
disregulation and thereby, improve functioning.
The study began with the central premise of determining how PD patients would
prioritize treatment for symptoms that could be alleviated with NFB and then designing
and testing NFB protocols to address those symptoms. This arose from my clinical
experience treating PD patients using NFB. For example, when I asked one PD patient
“what currently gets in the way of enjoying life?”, she responded “drooling”. Drooling is a
common symptom of PD, interfering with social interactions and self-concept (Nóbrega,
Rodriques, Torres, Scarpel, Neves, & Melo, 2008; Srivanitchapoom, Pandey, & Hallett,
2014). Though NFB can address balance, gait, tremor, and other symptoms one might
commonly assume patients would prioritize for treatment, this patient prioritized a
symptom that she felt was interfering with her ability to attend social events and interact
with other people.
Three inter-related studies comprise the overall research. First, I conducted a focus
group of PD patients to assess how they would prioritize symptoms for treatment. Next, I
conducted a pilot study to test the NFB intervention and procedures based on the focus
group discussion. Finally, I refined the NFB design based on the pilot study results and
conducted a larger intervention study.
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Focus Groups
The study began with a focus group in order to obtain firsthand information from
PD sufferers about how they would prioritize treatment for PD and to document these
priorities. The goal of the focus group was to help ensure that the final protocols for the
NFB component of the project align with the issues PD patients find most challenging and
to address their real life concerns. Focus groups are well suited for hypothesis testing and
forming a final framework for a quantitative study. The focus group process allows
participants to clarify their own thinking by comparing and contrasting their thoughts and
experiences with other group members (Axinn & Pearce, 2006). The point of the focus
group was not necessarily to quantify responses, nor to direct the conversation regarding
symptoms, but rather to more deeply understand and delineate core concerns of PD
sufferers that can be addressed by NFB.
Neurofeedback
A number of research studies have demonstrated the effectiveness of NFB for many
different issues, including Attention Deficit / Hyperactivity Disorder (ADD/ADHD) (Arns,
de Ridder, Strehl, Breteler, & Coenen, 2009; Gevensleben, Holl, & Albrecht, Vogel, C.,
Schlamp, D., Kratz, O., ... & Heinrich, H., 2009; Steiner, Frenette, Rene, Brennan, & Perrin,
2014), migraine (Walker, 2011), depression (Raymond, Varney, Parkinson, & Gruzelier,
2005), and optimal performance (Gruzelier, 2014), among many other issues. A smaller
number of studies have shown positive results on degenerative diseases, including PD
(Azarpaikan, Torbati, & Sohrabi, 2014; Erickson-Davis, Anderson, Wielinski, Richter, &
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Parashos, 2012; Esmail & Linden, 2014) and Alzheimer’s Disease (Berman & Frederick,
2009).
Several definitions and concepts are important for understanding the mechanics of
NFB. Frequency refers to the rate at which a brainwave repeats its cycle within one second.
Hertz (Hz) refers to the number of cycles per second. All areas of the brain express all
frequencies, or brain states. However, predominance of certain frequencies at each area of
the brain is desirable. A person with a healthy brain will shift through the different
frequencies depending on the task-at-hand. Most of the electrical activity from scalp EEG,
or the signal that can be obtained by placing an electrode on the scalp, falls in the range of 1
to 50 Hz. Amplitude refers to the magnitude of the various frequencies. There is general
agreement regarding the following frequencies for each state:
x

Delta (0-4 Hz): Delta is a slow, sleep wave that is present to various degrees
throughout normal brains when awake. It tends to be the highest in amplitude of
all states, with a normal amplitude range in adults of 15-18 (Demos, 2005).

x

Theta (4 to 8 Hz): Theta is slow waves that are often associated with drowsiness
such as that between sleep and wakefulness, with a normal amplitude range in
adults of 7-12 (Demos, 2005).

x

Alpha (8 and 12 Hz): Alpha is characterized by calm, relaxed, wakeful, and
meditative feelings, and is also associated with day dreaming and unfocused
thought, with a normal amplitude range in adults of 7.5-10.5 (Demos, 2005).

x

Beta (12-36 Hz): Beta is the most active brainwave and is associated with focus,
attention, and concentration. It dominates the normal waking state and is
subdivided into the following:
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o Sensory Motor Rhythm (SMR, 12-15 Hz): SMR waves are relaxed, but alert;
SMR is a specific type of low beta activity observed over the sensorimotor
cortex, and the normal amplitude in adults is 4-6 (Demos, 2005).
o Beta or Beta1 (15-18 Hz): Beta is associated with active attention, with a
normal amplitude range in adults of 3.5-4.5 (Demos, 2005).
o High beta or Beta2 (19-36 Hz): High beta is a hyper-alert band and is
associated with tension, anger, anxiety, and agitation; it has a normal
amplitude range in adults of 2.5-4 (Demos, 2005).
NFB uses single or multiple electrodes (or channels) placed via the standardized 1020 International System, which refers to the distances between adjacent electrodes – either
10% or 20% of the total front-back or left-right distance of the skull (American
Electroencephalographic Society, 1994).
Basic underpinnings of NFB include that the brain becomes disregulated for various
reasons or combinations of reasons (injury, disease, stress), and this disregulation impedes
optimal functioning. Quantitative EEG (QEEG), also referred to as brain mapping, has
shown the different parts of the brain and their respective functions. Moreover, previous
studies have shown that imbalances for different issues (e.g., depression, anxiety, ADHD,
migraine) relate to distinctly different parts of the brain. For some conditions, NFB involves
single areas of the brain but more often, multiple areas are affected by disregulation (i.e.,
comorbid manifestations of the disregulation such as multiple sclerosis and depression or
ALS and anxiety). NFB offers an appealing option for treatment because it is non-invasive,
medication side effects are avoided, and NFB itself has few if any side effects (Soutar &
Longo, 2011; Larsen, 2012).
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NFB has proven effective even for very serious conditions. In a poignant example,
Bolea (2010) demonstrated the efficacy of NFB in a case study of an inpatient paranoid
schizophrenic who had been hospitalized 20 years. After approximately 18 months of NFB
and 130 sessions, this patient was released to the community. The author documents the
successful treatment of more than 70 inpatient schizophrenics, with long-term follow-up
indicating the retention of improvements two years post-treatment. See Appendix A, brain
map examples, for illustrations of different areas of the brain responsible for various
cognitive, emotional, and sensory functioning.

Problem Statement
Previous studies have shown the multiple areas of life affected by PD, including
depression, anxiety, and loss of cognitive function, in addition to the physical symptoms of
the disease itself (Den Oudsten, Lucas-Carrasco, Green, & The WHOQOL-DIS Group, 2011;
Schipper, Dauwerse, Hendrikx, Leedekerken & Abma, 2014). However, no previous
research has addressed how PD patients would prioritize treatment. It stands to reason
that tremor, balance and gait would be among the top priorities for patients. However,
other issues may interfere more with activities of daily living (ADLs) and QOL than the
issues more typically associated with the disease. These other issues may include factors
that inhibit social interaction or create embarrassment (facial expression, soft voice,
drooling, incontinence) or the ability to fully embrace life (depression, motivation/apathy).
Research has also shown a relationship between gait and cognition in PD patients.
Ricciardi, Bloem, & Snijders, Daniele, Quaranta, Bentivoglio & Fasano (2014) conducted
clinical and neurological assessments at rest and during walking on a control group (no PD)
and three groups of PD patients: (1) without freezing of gait (2) with levodopa-responsive
7

freezing (3) with levodopa-resistant freezing. Levodopa is a drug used to increase
dopamine in PD patients. Compared to PD patients without freezing, those with levodoparesistant freezing performed worse when tested at rest on tests of phonological verbal
fluency (p = .01). Walking was associated with a paradoxical improvement of phonological
verbal fluency in patients with levodopa-resistant freezing (p=.04). This helps demonstrate
the link between treatment of different PD symptoms and how an improvement or decline
in one symptom may contribute to a similar result in a different symptom, thus
underscoring the importance of considering comorbid symptomatology in PD treatment.
In regards to NFB research, most studies focus on a single protocol, attempting to
demonstrate effectiveness on a chief area of concern (e.g., Azarpaikan, 2014). While the
single protocol methodology may show effectiveness for the concern being addressed, for
degenerative diseases, they do not take into account comorbid issues that typically
accompany the disease. These issues can include depression, anxiety, and loss of cognitive
function, in addition to the physical symptoms of the disease itself. These comorbid issues
affect different parts of the brain and are addressed using distinctly different NFB
protocols. A comprehensive, holistic approach to NFB with degenerative diseases is
required to address comorbid issues that accompany these more serious conditions, and
this research has received little attention to-date.

Research Questions
The study is designed in 3 segments to answer the following questions using both
qualitative and quantitative analysis methods:
(1) Focus group
x

How do Parkinson’s Disease (PD) patients prioritize challenges resulting from PD?
8

(2) Pilot Study
x

Can improvements to the QEEG be observed with mid-stage Parkinson patients with
relatively few neurofeedback sessions?

x

Is there an association between NFB treatment and tremor measures or overall
disability scores?

x

Can any changes in outcome measures be associated with specific NFB protocols?

(3) Intervention Study
x

Do tremor scores improve following NFB treatment? How do tremor scores change
1-month post-treatment?

x

Do cognition scores improve following NFB treatment? How do cognition scores
change 1-month post-treatment?

x

What qualitative changes, if any, do participants report during and 1 month
following neurofeedback treatment?

x

How does the EEG pattern at sites treating tremor and cognition change following
NFB treatment? Are any changes sustained 1 month post-treatment?

9

Chapter 2. Literature Review
Parkinson’s Disease
While common features of PD have been well-documented, the disease is noted for
its heterogeneity (Foltynie, 2002), which creates challenges in standardizing treatment
protocols at any stage of the disease. The most common initial symptoms of PD are motor
symptoms such as tremor and bradykinesis (slowing of movement) (Uitti, Baba, Wszolek &
Putzke, 2005). However, the assessment of non-motor symptoms is increasingly
recognized as critical in treatment of PD, as they are often as problematic as motor
symptoms and therefore, must be addressed as part of holistic treatment of the disease
(Bayulkem & Lopez, 2011).
Standard treatment can be generally grouped into two categories, symptomatic and
neuroprotective. There are currently no neuroprotective treatment measures for PD, thus
all treatment is geared toward alleviating symptoms. PD is thought to occur due to too little
dopamine in the brain (Dirkx, den Ouden, Aarts, Timmer, Bloem, Toni, & Helmich, 2017).
Therefore, the chief medication intervention, carbidopa-levodopa (brand name Sinemet) is
designed to boost dopamine. Levodopa changes to dopamine in the brain and carbidopa
prevents the breakdown of levodopa, which allows more of the drug to enter the brain. A
key issue is wearing-off while take the drug, i.e., a lack of sustained improvement between
doses and a return of symptoms prior to the time for the next dose. Studies have shown
that the treatment initiation soon after diagnosis leads to an improved QOL (Grosset,
2006). However, long-term use of levodopa medications is associated with wearing-off and
an increase in dyskinesia (involuntary movement). Therefore, the timing of when to begin
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medication treatment is debated. Other medications have also demonstrated benefit in
early PD (Caslake, Macleod, Ives, Stowe & Counsell, 2009), however they are accompanied
by significant side effects including serious impulse control issues in some patients
(Antonini & Cilia, 2009). Recent research has linked anticholinergic drugs, which are used
to treat movement disorders, including PD, with dementia in older adults (Coupland, Hill,
Dening, Morriss, Moore, & Hippisley-Cox, 2019; Gray & Hanlon, 2018).
About half as many women as men are diagnosed with PD, and theories about
gender differences include the role of estrogen, which is thought to be neuroprotective and
assist in the production and retention of dopamine (Wooten, Currie, & Bovbjerg, Lee &
Patrie, 2004). Studies have also shown that levodopa requirements in PD vary substantially
and that women use less levodopa than men (Nyholm, Karlsson, Lundberg, & Askmark,
2010). Three types of tremor are distinguished: (1) resting (no movement) (2) postural
(e.g., extending an arm or leg), and (3) action (e.g., picking up and holding a cup) (Dai,
Zhang & Lueth, 2015).
Exercise has been shown to improve and even delay PD symptoms (Duchesne,
2015). One popular and well-researched exercise program is Big and Loud, in which
participants are trained to make bigger motor movements (i.e., steps) and to speak more
loudly (Bowers, 2016; Fox, Farley, Ramig, & McFarland, 2005). As the disease progresses
from moderate to severe stages, deep brain stimulation implants are an alternative
treatment, albeit with significant risks, including improvement in some symptoms but
worsening in others (Angeli, Mencacci, Duran, Aviles-Olmos, Kefalopoulou, Candelario … &
Foltynie, 2013). Due to the long course and slowly progressive nature of PD, treatment can
last 20 years or longer. Parkinson’s is typically not fatal and treatment is lifelong from the
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time of diagnosis. Studies have shown that people who die with PD have a higher mean
number of causes of death (comorbidities) than matched controls (Lethbridge, Johnston, &
Turnbull, 2013).

Focus Group
In a qualitative study that included focus groups and interviews with people with PD
and close family members, researchers documented the wide-ranging health issues
resulting from PD. These issues involved physical health such as gait, balance, and fatigue;
mental health, such as depression and anxiety; and cognition, such memory, word-finding,
and attention. Group members discussed how these issues combine to affect virtually every
aspect of life, including personal relationships (spouse, children, grandchildren); social
functioning (extended family, friends); and work (career, volunteering). It becomes difficult
for patients and practitioners to delineate comorbidities, including which symptoms take
priority and which may be contributing to others (Schipper, Dauwerse, & Hendrikx, et al.,
2014; Friedman, Brown, Comella, Garber, Krupp, Lou … & Taylor, 2006). The study
concluded that to improve quality of life, multiple factors should be taken into
consideration (Dauwerse, Hendrikx, & Schipper, 2014).

Neurofeedback Intervention
Neurofeedback evolved beginning in 1924 when Hans Berger, a Swiss psychiatrist,
invented electroencephalography (EEG) and became the first to describe differential
rhythms present in normal and abnormal brains (Wiedemann, 1994). Further development
is largely credited to Joe Kamiya and Barry Sterman. In 1958, Kamiya, a psychologist
teaching at the University of Chicago, showed that subjects could control their brainwaves,
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which were previously thought to be involuntary (Kamiya, 1962; Kamiya, 1979). With
sensors attached to the head, subjects first guessed whether they were producing alpha
waves and received verbal feedback as to whether their guesses were correct or wrong. By
the fourth day of training, subjects’ guesses were 100% correct. Next, Kamiya showed that
subjects could begin or stop producing alpha waves on cue, thus demonstrating the
trainability of brainwaves and the behavior they govern.
Sterman, now Professor Emeritus, Departments of Neurobiology and Biobehavioral
Psychiatry, University of California at Los Angeles (UCLA) began experiments in the mid1960’s involving the operant conditioning of cats to increase their Sensory Motor Rhythm
(SMR) across the Sensory Motor Cortex. Later, working with the same cats from his lab to
help NASA test the effects of lunar landing fuel, he realized that the cats that received SMR
training were more resilient – and even immune – to the effects of the fuel. This was the
first demonstration that neurofeedback could positively affect a neurological disorder. As a
result, NASA began SMR neurofeedback training for astronauts (Othmer, 2004).
Neurofeedback use and research grew substantially in the following decades. Brain
mapping revealed more parts of the brain and their respective functions. Further, studies
showed that imbalances for different issues relate to distinctly different parts of the brain,
including depression (Cheon, Koo, & Choi, 2016), anxiety (Hammond, 2005), autism
spectrum disorders (Thompson, Thompson, & Reid, 2010), and migraine (Walker, 2011).
The National Institutes of Health (NIH) has funded 281 neurofeedback studies since 2005,
with 45 of those projects currently active (NIH RePORT, 2019). The awards were funded
across several different NIH Institutes and Centers, indicating a wide interest in the
applications of neurofeedback. Neurofeedback offers an appealing option for treatment
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because it is non-invasive and does not involve medication. Therefore, side effects from
medication are avoided, and NFB itself has few side effects (Larson, 2012; Luctkar-Flude &
Groll, 2015).
The brain map shown in Figure 1 indicates neurofeedback training sites based on
the international 10-20 system (Okamoto, Dan, Sakamoto, Takeo, Shimizu, Kohno … & Dan,
2004; American Electroencephalographic Society, 1994). The nose is at the top of the
screen. C3 and C4 are on the sensory motor strip and are associated with functions of the
arms, hands, and legs, and this is where tremor is treated. FP1, on the left forehead, is
associated with attention, focus, getting things done, and planning (Kaller, Rahm, Spreer,
Weiller, & Unterrainer, 2011; Reid, Bzdok, Langner, Fox, Laird, Amunts … & Eickhoff 2016).
Figure 1. International 10-20 brain map.

Brain mapping, has shown that people with Parkinson’s have excess slower brain
waves but insufficient faster waves, a pattern associated with gait imbalance, compared to
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controls (Han, Wang, Yi, & Che, 2013). Intervention studies have used NFB to demonstrate
improvements in balance with early stage Parkinson’s patients. For example, Azarpaikan,
Torbati, & Sohrabi (2014) conducted a study with 16 early-stage PD patients, half of whom
underwent NFB training to improve balance and gait, while the other half were assigned to
a control group. The intervention group (IG) underwent eight 30-minute NFB sessions and
controls received sham NFB. The researchers performed NFB at the O1-O2 (bilateral
occipital area), hypothesizing that brainwave improvements in this area would increase
attention and translate to better focus and improvement in gait and balance. The occipital
lobes are “associated with visual processing, sequential memory functions, and arousal …
[and] they have connections with the cerebellum … which affects balance and the
amygdala” (Soutar & Longo, 2011). The goal of the intervention was to yield a positive
effect on static and dynamic balance by increasing low beta waves (beta1, 15-18 Hz), which
are associated with focus and “relaxed alertness”, and decreasing theta waves (4-7 Hz),
which can be associated with daydreaming and slow movement, at O1-O2.
The researchers found improvements in the IG for both static and dynamic balance
(p <.001), as well as increases in the beta1 mean (p <.001) and decreases in theta mean (p
<.001), leading the authors to conclude that NFB can improve balance for early stage PD
patients with relatively few NFB sessions and demonstrating the efficacy of NFB at O1-O2
for PD patients.
In a case study, Ibric (2016) demonstrated the reduction of tremor for an elderly
patient with a 24-year history of tremor using the C3-C4 (bilateral central brain) NFB
protocol, as will be used in the present study. Erickson-Davis, Anderson, Wielinski, Richter,
& Parashos (2012) conducted a study with PD patients to assess whether NFB could have a
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positive effect on levodopa-induced dyskinesia (LID). Nine participants were randomized
into intervention (NFB) and control (sham NFB) groups and underwent 24 NFB or sham
sessions. NFB targeted SMR, similar to Azarpaikan, et al. (2014), but was conducted at C3C4. Diaries kept by study subjects during the course of the training indicated decreases in
motor fluctuations and dyskinesia severity for the intervention group compared to
controls, though the improvements were not statistically significant. These differences
were accompanied by significant changes in subjects’ resting state cortical activity baseline
to post-treatment. However, there were no statistically significant differences between the
intervention and control groups in primary outcome measures assessing change in
dyskinesia severity, nor in secondary outcome measures assessing change in clinical
features of PD. It should be noted that this study had statistically significant differences
between the intervention and control groups in terms of age and average number of hours
per day (a) ON without dyskinesia and (b) with non-troublesome dyskinesia.
Cognitive function (planning, working memory, attention) is treated with NFB in the prefrontal or frontal lobes of the brain. Research has demonstrated improvements in cognitive
functioning with relatively few NFB sessions. For example, Hosseini, Pritchard-Berman, Sosa,
Ceja & Kesler (2016) used NFB to train the pre-frontal cortex to test changes in cognitive
functions. Ten healthy participants received NFB and 10 received sham NFB. Compared to the
sham condition, participants who received NFB showed significantly improved executive
function including measures of working memory after just four sessions (100 minutes) of
training. Haddadi, Rostami, Moradi & Pouladi (2011) conducted frontal and temporal lobe
NFB with children to address issues of learning and memory due to acquired brain injury
following surgery for brain tumors. Pre- / post-intervention assessments showed significant
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improvements in the Wechsler Intelligence Scale for Children (WISC) and the Child Behavior
Checklist (CBCL). Subjects received 40 NFB sessions (45 minutes per session, 3 times per
week). NFB targeted decreasing theta activity (4-7 Hz) and increasing beta (15-18 Hz). Wang
and Hsieh (2013) conducted a randomized controlled study to test the effect of frontal lobe
training, and any impact on cognitive performance, on older (age 61-72) versus younger (age 2124) subjects. 32 participants were assigned to NFB or sham-NFB groups and underwent 12
training sessions over 4 weeks. Results showed significant improvement in orienting scores in
the older neurofeedback training group. In addition, the training was found to improve working
memory function in the older participants.
PD treatment typically includes medication protocols that address the physical
aspects of the disease (e.g., tremor) but not necessarily other aspects, especially early in the
diagnosis (Connolly & Lang, 2014). Few to no long-term side effects have been reported for
neurofeedback training (Soutar and Longo, 2011; Niv, 2013). In a survey of NFB
practitioners conducted by Cuthbert (2003), 4% reported any adverse reactions, most of
which were mild and transient. In fact, a significant factor in the demand for NFB treatment
is the avoidance of side effects, including those that are common with medication. Shortterm side effects of NFB include fatigue, which typically subsides after a rest period.
Treatment is painless.
In conclusion, treatment for PD is life-long from the time of diagnosis, often lasting
20 years or more. Standard treatment is focused on improving or delaying symptoms, and
while medication is typically helpful for symptom alleviation, it also requires higher doses
and becomes less effective as the disease progresses. Focus groups with PD patients have
documented the wide-ranging symptoms of the disease, which are only partially addressed
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by standard treatment. NFB has a long history of addressing serious mental and physical
health problems, and recent NIH funding demonstrates interest in NFB for addressing a
broad spectrum of issues. NFB has shown promise in improving symptoms affecting PD
patients, including balance, gait, tremor, and motor fluctuations. Also, NFB to address
cognitive function showed improvements in older people compared to younger people.
However, no research to-date has examined the impact of using NFB to address comorbid
symptom treatment in PD, nor the impact of NFB for cognitive symptoms of PD.
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Chapter 3. Methods
Three interrelated studies comprise this research. I conducted a focus group to
ascertain how PD patients would prioritize symptom treatment that could be improved
with neurofeedback. Key issues identified by the focus group were tremor and planning.
Next, I designed and carried out a pilot study to test NFB protocols aimed at improving
tremor and planning, as well as broader quality of life outcome measures. Finally, I refined
the design and measures and carried out an intervention study.

Focus Group
Participants
Study participants were recruited via flyers at two large, local neurology offices and
the local area Parkinson Support Group. A sample script for the support group meeting is
provided as Appendix B. Interested persons were instructed to telephone or email the
investigator within a given period of time. Persons eligible to participate in the study were
those (1) with a diagnosis of PD (2) without significant psychiatric comorbidity and (3)
without a significant physical health problem other than PD. “Significant psychiatric
comorbidity” was defined as diagnosed dementia, major depressive disorder (MDD),
bipolar disorder, or personality disorder. “Significant physical health problem” was
defined as any condition that may impede the person’s ability to fully participate in the
group (e.g., affecting the ability to speak).
Informed Consent (IC) Process. I telephoned each potential participant to inform
her/him of the focus group date and to confirm continued interest. Upon arrival at the
session, the informed consent document (provided as Appendix C) was provided to each
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participant. I reviewed the consent form with each participant, answered questions, and
requested a on the consent document.
Measures
A focus group discussion guide, provided as Appendix D, was designed to guide the
focus group conversation. The purpose of the discussion was to elicit themes related to PD
symptoms that could be improved with neurofeedback in order to help inform the pilot
study. Participants were asked to delineate and prioritize issues they face on a regular
basis, as well as those that occur less often, and the impact of changes in functioning related
to PD. Core questions were as follows:
x

My first question has to do with how Parkinson’s has affected you lately. When you
think about your ability to enjoy life over the past month, in terms of Parkinson’s,
what has gotten in the way?

x

Now, thinking about the last 6 months to a year, when you think about your ability
to enjoy life over this longer timeframe, in terms of Parkinson’s, what are the issues
that have gotten in the way?

x

My next question is, how impactful are the changes to functioning that you
described in the two first questions in terms of your ability to enjoy life?

Design
The focus group study was designed to elicit responses from PD patients about how
they would prioritize symptoms for treatment that would improve quality of life.
Discussion was not directed toward specific symptoms but rather allowed to evolve
organically based on participants’ experiences and responses.
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Procedures
This focus group was held at local university with the necessary facilities and
technology to hold and record the group, including video- and audio-recording. The
building was handicap accessible and had space where people who accompanied focus
group participants could wait. Upon arrival for the focus group, each person read and
signed the informed consent document.
To mediate the potential for emotional upset due to talking about sensitive topics, a
list of support activities for PD in the local area was provided to participants. Also, a break
was built-in to the discussion schedule. An additional risk involves informational risk, or
the risk of participants sharing information about each other. To help mitigate this, the
informed consent document included explicit language about not sharing information
learned through participating in the focus group, as well as using relationship references
(e.g., “my son”) and not names.
Each person was provided a pad of paper and pen. The focus group facilitator
paused after asking each major question so that participants could gather their thoughts
and write down responses if they wished.
Participants were given a $20 gift card each as a token of appreciation for
participating in the group. Participants arranged their own travel to the group. Parking was
free. The total time commitment for participating in the group was 3 hours.
Data Analysis
Data analysis consisted of thematic analysis of stories to described the group
conversation and determine themes that emerged. Thematic analysis is a “method for
identifying, analyzing and interpreting patterns of meaning (“themes”) in qualitative data”
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(Clarke & Braun, 2017, p. 297). The focus of the analysis was on both evaluating
commonalities among participants and preserving the uniqueness of each of their stories
and experiences. Data were transcribed and the video and audio recordings were used to
verify the speakers and the conversation. The themes that emerged were generally
categorized into issues that could be addressed by NFB (e.g., tremor, balance) and those
that could not (e.g., relationships with family members). Of the issues that could be
addressed by NFB, mentions of each issue were tallied and the conversation regarding the
impact of these issues was evaluated (e.g., number of participants who indicated each issue
was problematic, severity of impact on daily living). The issues that emerged from the focus
group as affecting every group member were tremor and activity planning.

Neurofeedback Pilot Study
A NFB pilot study was designed to test protocols and procedures developed in
response to focus group results. The most highly prioritized issues identified were (1)
tremor and (2) planning. NFB protocols that address tremor are on the sensory motor strip
across the brain midline (ear-to-ear) and specifically, C3 and C4. These sites are associated
with function of the arms, hands, feet, and legs.
The frontal and pre-frontal sites of the brain relate to the temporal organization of
behavior, speech, and reasoning and critically participate in working (short-term) memory,
preparing for action, and control interference (Fuster, 2008). Planning can be addressed in
the left hemisphere frontal and pre-frontal areas (FP1, F3, F7). FP1 was selected because it
is associated with planning, as well as motivation and apathy, and apathy is common in PD
(Pluck & Brown, 2002). Prefrontal sites have been demonstrated to help increase
neuroplasticity and improve executive function (Gomes, Ducos, Gadelha, Ortiz, Van Deusen,
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Akiba … & Dias, 2018) and a recent study by Aminov, Rogers, Johnstone, Middleton &
Wilson (2017) showed that the severity of EEG dysregulation with a single electrode
placement at FP1 following a first-ever stroke was moderately to highly correlated with 90day post-stroke cognitive outcomes.
Participants
Recruitment. Study participants were recruited via flyers at local neurology offices and
Parkinson support group meetings.
Eligibility. Eligibility criteria were established to ensure comparability between
participants on broad areas of functioning and overall status. Criteria and the reasoning for
each was as follows:
(1)

With a diagnosis of Parkinson’s Disease (a confirmed diagnosis was necessary to
create homogeneity within the sample; patients report suspecting PD for some
time prior to formal diagnosis);

(2)

With mid-stage Parkinson’s Disease (previous work has shown NFB benefit with
early stage patients but no work has addressed later PD stages; also, mid-stage is
the longest stage of the disease);

(3)

Without psychiatric comorbidity (e.g., diagnosed dementia; comorbidities such
as dementia or serious mental illness would indicate significant brain
dysregulation, in addition to dysregulation present that is related to PD alone);

(4)

Without previous neurofeedback treatment (previous NFB would create a
disparity between participants in that any brain dysregulation present may have
already been at least partly addressed by the previous treatment);
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(5)

Without a deep brain stimulation (DBS) implant (implants may interfere with
the EEG signal and therefore, the NFB training).

Mid-stage PD is characterized as follows:
x

Significant slowing of body movements

x

Early impairment of equilibrium on walking or standing

x

Generalized dysfunction that is moderately severe
Participants were randomly assigned to the intervention groups, while the control

person requested assignment based on convenience.
Measures
Participants were given the WHODAS prior to the NFB intervention, at the
conclusion of the intervention, and 1-month post-intervention to assess changes pre- and
post-intervention, as well as the degree to which any changes were sustained for a month
after treatment ended. The WHODAS includes six domains, as follows: cognition
(understanding and communicating), mobility (getting around), self-care, getting along
with people, life activities, and participation in society. The understanding and
communicating domain was used to assess changes in cognition and includes cognitive
functions such as: concentrating on doing something for 10 minutes, remembering
important things, analyzing and finding solutions to problems in day-to-day life, and
learning a new task (e.g., how to get to a new place). The WHODAS is provided as Appendix
E. An iPhone application, Study My Tremor, was used to assess any changes in tremor. Study
My Tremor requires that a person hold the iPhone with an open palm, and the application
then records tremor frequency (hertz), power (milliwatts), amplitude (millimeters), and
synchronization (steepness of the main peak) (Study My Health, 2018).
24

QEEGs were done prior to treatment and at the end of treatment. As the
intervention progressed, participants noticed changes in functioning (e.g., less freezing of
gait) and volunteered these observations, which were documented.
Design
The pilot tested two NFB protocols, as will be described, and compared results of
participants in the two protocol groups to each other and to a control (wait-listed) group.
The wait-listed group received the intervention that worked best after the 1-month
followup. The design is depicted in Table 1. Pilot study design representation.
Table 1. Pilot study design.
R (Intervention A)
R (Intervention B)
N (Control)

Pretests
O
O
O

Intervention
Xa
Xb
--

Posttests
O
O
O

1 Month Followup
O
O
O

Intervention
--X a or b

R=Random assignment; N=Non-random assignment; O = Observation; X=Intervention

The pilot included C3 and C4 on the sensory motor strip to address tremor and FP1
on the left forehead to address planning, with one person assigned to each of 3 conditions
(refer to Figure 1).
The sensory motor (SM) condition included C3 and C4 and 12 sessions of 20
minutes each, for a total of 4 hours of NFB. The second condition included C3 and C4, plus a
cognition protocol (SM+Cog) at FP1 for a total of 8 hours of NFB. The length of each NFB
session was selected based on previous research (e.g., Azarpaiken, et al., 2014). At C3-C4,
the sensory motor rhythm (12-15 hertz) was reinforced and theta (4-7 hertz) and high beta
(22-36 hertz) were inhibited. At FP1, beta (15-18 hertz) was reinforced and theta and high
beta were inhibited. Participants received 1-2 sessions per day over 2-3 weeks. On days
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with two sessions, a 2-hour or longer break was taken between sessions. The treatment
groups were blinded to the protocols.
The third condition was a control, with no treatment. Table 2 summarizes the
design. Brainmaster Avatar (Brainmaster, 2016) equipment was used to obtain the
Quantitative Electroencephalograms (QEEGs). Neurofeedback was conducted using EEGer
version 4.3 (EEGer, 2016).
Table 2. Pilot study protocol design.
Group

Description

Placement Sessions

1

Sensory Motor
(SM)
SM+Cognition
(SM+Cog)
--

C3-C4

12

C3-C4 +
FP1-A2
Control

12
12

2
3

Minutes per
Session
20

Total Hours
Neurofeedback
4

20
20
--

8
--

Procedures
Major steps in the intervention study included:
(1) Make group assignment;
(2) Conduct pre-test (WHODAS) and QEEG
(3) Carry out intervention
(4) Conduct post-test (WHODAS) and QEEG
(5) Conduct 1-month post-tests
(6) Conduct NFB for waitlisted group
(1) Group assignment. At the end of the recruitment period, equal number group
assignments were made as follows (1) NFB protocol A (2) NFB protocol B and (3)
wait-listed (control).
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(2) Pre-tests. Upon arrival for the first session, each person was consented (see
Informed Consent Process), QEEG data were acquired, and pre-tests were conducted
using the following assessments:
x

World Health Organization Disability Assessment Schedule (WHODAS), version
2.0 (written, self-administered; participant responds to questions on a 5-point
scale about quality of life);

x

Study My Tremor iPhone Application (assessments of tremor strength and
frequency).

The investigator administered the WHODAS and the tremor assessment. The pre-tests
were conducted at the clinical office of the investigator.
(3) Intervention. The intervention consisted of 12 NFB sessions over 3 weeks. Sessions
were held at the clinical office of the investigator. For Intervention group A, the
intervention (NFB) lasted 20 minutes per session, with approximately an additional
10 minutes of setup time. For Intervention group B, sessions lasted approximately
40 minutes with approximately an additional 20 minutes of setup time. NFB for the
two protocols for group B (SM+Cog) was done sequentially (not simultaneously).
Table 3 shows the NFB protocols.
Table 3. Pilot study NFB protocols.
Intervention
A

B

Location

Reward

Central
Frontal

12-15
15-18

Inhibit
4-7
4-7

Sessions

22-36
22-36

12
12

Minutes/
Session
20
20

Placement
C3-C4
FP1-A2

(4) Post-test. Groups A and B completed the intervention within approximately the
same (3 week) timeframe. Within one week of completing session 12 (the last NFB
session), the physical and mental health assessments were repeated in the same
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manner as the pretest (at the clinical office using the same rooms and process) with
both intervention groups and controls, and the QEEG was repeated.
(5) 1 Month post-test. 30 days post-intervention, the physical and mental health
assessments were repeated in the same manner as the pretest (at the same office
location using the same rooms and process).
(6) NFB for wait-listed group. After the 1-month post-test was completed, the waitlisted group was provided Intervention B (both protocols).
Outcome Measures
Outcomes were assessed based on changes to the QEEG and QOL measured by the
World Health Organization Disability Assessment Scale (WHODAS) 2.0. The WHODAS 2.0 is
a 36-item assessment of physical and mental health and disability that has been validated
internationally (Garin, Ayuso-Mateos, & Almansa, et al., 2010; ǆ stǅ n & World Health
Organization, 2010). The assessment items are equally distributed across six domains and
provide a standardized disability level (percentage) for each domain and overall. The six
component domains are: Cognition (understanding and communicating); Mobility (moving
and getting around); Self-care (hygiene, dressing, eating and staying alone); Getting along
(interacting with other people); Life activities (domestic responsibilities, leisure, work and
school); and participation (joining in community activities) (WHO, 2017).
The WHODAS has been used to describe functioning and disability with chronic
conditions (Cieza, Bostan, Ayuso-Mateos, Oberhauser, Bickenbach, Raggi … & Chatterji,
2013), including Parkinson Disease (Chagas, Moriyama, Felício, Sosa, Bressan & Ferri,
2014; Raggi, Leonardi, Ajovalasit, Carella, Soliveri, Albanese & Romito, 2010). The
WHODAS is highly correlated with the WHO Quality of Life (WHOQOL, r = 0.68), thus it is a
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robust measure of QOL as well as specifically designed for those with disability (Ustün,
Chatterji, Kostanjsek, Rehm, Kennedy, Epping-Jordan … & WHO/NIH Joint Project, 2010).
I also recorded anecdotal information that participants volunteered. Tremor
measures were taken using a phone application; however, the measure proved to be
inconsistent (e.g., back-to-back readings that were highly variable, differences in readings
based on slight differences in how participants held the phone) and therefore, results are
not included.
There were no monetary incentives or cost for participating in the study.
Participants arranged their own transportation.
Data Analysis
The independent variable was group assignment, and the key dependent variable
was the WHODAS overall disability score. WHODAS sub-scores were also examined. The
EEG data acquired for the brain maps were analyzed using Neuroguide software (Applied
Neuroscience, Inc., 2016). The resulting brain maps were manually reviewed for pre- and
post-treatment differences for each of the 3 conditions. Verbatim statements from the
qualitative data were summarized.

Neurofeedback Intervention Study
The intervention study utilized a single subject design (SSD) with multiple subjects,
and included two EEG baseline measures prior to the intervention at the treatment sites
taken one week apart. An ABA design was used, in which there was a single transition
between baseline (A) and the intervention (B), followed by one month with no
intervention, or a withdrawal of treatment (A) and a final measurement. Two baseline EEG
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measures were done to help substantiate pre-intervention status. All study measures
(WHODAS, UPDRS PQ, and EEG measures) were taken at pre-test, post-test and 1-month
following post-test.
The SSD is well suited for studying the effect of a clinical intervention by providing
flexibility in individual pre-intervention differences and response to the intervention
(Zarate, 2015; Denman, Banajee & Hurley, 2015; Lobo, Moeyaert, Baraldi, & Babik, 2017).
As established in the pilot study and documented in the literature (e.g., Rana, Siddiqui, &
Yousuf, 2012), symptoms can vary significantly in Parkinson’s. The SSD allows each
participant to serve as her or his own control, thereby helping to eliminate skewing of
results due to individual participant differences that are likely to be present in this type of
sample. Based on results from earlier studies (e.g., Azarpaikan, et al.), effect can be
established with relatively modest sample sizes.
Modifications to the intervention study based on results of the pilot were as follows:
x

Use an SSD.

x

Drop the mid-stage PD diagnosis requirement for participation.

x

Add the patient questionnaire (PQ) from the Movement Disorder Society (MDS)
Uniform Parkinson’s Disease Rating Scale (UPDRS; International Parkinson and
Movement Disorder Society, 2008) as an outcome measure to capture any changes
in tremor (replacing the tremor app). The PQ is provided as Appendix F.

x

Provide all participants with the same protocol (SM+Cog).

x

Use the PQ tremor question to assess tremor changes and use the WHODAS
cognition domain to assess cognitive changes (key dependent variables).
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Participants
Participants were recruited using Facebook groups (people interested in PD), as
well as from local PD support groups and neurologists, similar to the pilot study. Local PD
exercise groups were also used for recruitment. Facebook recruitment generated interest
and contacts regarding the study. However, most participants were recruited from local PD
exercise classes. Unlike the pilot study, the criterion that participants be mid-stage PD was
dropped. The pilot study showed variation in QEEG data, even for participants within the
same disease stage, indicating that patients in the same disease stage can have
substantially different types of brain disregulation. Studies have demonstrated that
symptoms can vary widely within the same disease stage, making staging difficult (Rana, et
al., 2012) and that currently used scales are skewed toward moderate and severe PD and
do not adequately capture non-motor symptoms that impact staging (Getz & Levin, 2017).
Further, studies have shown the lack of homogeneity within disease stage, as well as the
lack of linearity of the progression of the disease, indicating the impact of risk and
protective factors on functioning (Maetzler, Liepelt, & Berg, 2009).
Inclusion criteria for the intervention study were:
(1)

With a diagnosis of Parkinson’s Disease.

(2)

Without psychiatric comorbidity (e.g., diagnosed dementia).

(3)

Without previous neurofeedback treatment.

(4)

Without a deep brain stimulation (DBS) implant.
Participants were continuously enrolled until a sufficient number of participants

was achieved.
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Measures
The key outcome measures (dependent variables) were the PQ tremor score and the
WHODAS cognition disability percentage. The PQ was used to measure any changes in
tremor (replacing the tremor app). Patient report for both motor and non-motor aspects of
PD has been shown to be equal to or superior to clinical assessments. For example, in a
study of 300 Parkinson’s patients designed to assess differences in identification of
wearing-off, Stacy, et al. (2005) showed that patients more frequently identified wearingoff using a patient questionnaire than clinicians using clinical assessment tools. Prashanth
and Sumantra (2018) used the patient questionnaire portion of the MDS-UPDRS to develop
prediction models using machine-learning techniques that could classify early PD from
healthy normal patients, which resulted in greater than 95% accuracy.
A qualitative component to outcome measures, anecdotal information that
participants reported (e.g., improvements in movement that may not be captured in the
self-reported scales) was also added. This information was solicited at the beginning of
each NFB session by asking “Have you noticed any changes”? and recording responses in a
spreadsheet based on session number (i.e., reports for all participants at session 1 were
recorded in the same column), with individual participants identified in rows, so that
changes participants noticed at the same or similar point in the intervention could be
compared. Session date for each participant was also recorded in order to track days
between sessions and total length of the intervention for each participant. Participant
reports were recorded verbatim or summarized with minimal editing. Any summaries
were repeated back to participants to ensure accuracy.
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Design
NFB was carried out for 20 minutes at each training site, as with the pilot study.
However, for the intervention study, 20 sessions were conducted (instead of the 12
conducted for the pilot). The additional sessions were done in an attempt to more clearly
establish any changes that may be attributable to the intervention. Also, all participants
received the same intervention (SM+Cog). Differences in brain disregulation identified in
the pilot and previous research (Getz & Levin, 2017) led to the conclusion that it would be
difficult to specifically attribute changes in functioning to receiving the SM protocol versus
the SM+Cog protocol. The cognition domain on the WHODAS was used to assess specific
changes in cognition.
Tables 4 and 5 show the overall study design and intervention protocol design,
respectively. Table 6 provides a summary of the specific NFB protocols. Each participant
signed a consent form prior to the study (see Appendix G).
Table 4. Intervention study protocol design.
Description

Protocol

Sessions

Sensory Motor (SM)
Cognition (Cog)

C3, C4
FP1

20
20

NFB Minutes
per Session
20
20

Table 5. Intervention study NFB protocols.
Placement

Reward

Inhibit

C4

12-15

4-7

22-36

C3, FP1

15-18

4-7

22-36
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Total Hours of
Neurofeedback
13.3

Procedures
Approval for the study was received from the Western Michigan University
Institutional Review Board (IRB). Informed consent was obtained from all participants and
extra care was taken to ensure participants understood (a) the overall protocol (b) risks
and benefits, including that the protocol may not improve PD or other symptoms and (c)
that they may withdraw from the study at any time. The intervention was conducted at my
clinical office using the same methods and procedures established in the pilot. Brainmaster
(version 1.5.9) neurofeedback equipment was used (Brainmaster, 2016).
Data Analysis
Intervention study data were examined utilizing descriptive and qualitative analysis
methods. EEG recordings were taken at the 3 study timepoints (pretest, posttest, and
followup), with 2 pretest measures taken 1-week apart. The average amplitude for each
waveband included in the intervention for each training site (C3, C4, FP1) was graphed and
compared across measurement time points.
Intervention effect based on level, trend, and variability of change to the tremor and
cognition dependent variables was assessed, and this was done by comparing participants’
individual results across measurement timepoints based on years since diagnosis and
participant age. Qualitative information that participants reported while receiving the
intervention and at the 1-month followup was examined based on when participants
noticed changes (i.e., at what session number). Participant reports are provided verbatim
or summarized. Attention was paid to the ABA design and specifically, whether any
improvements reported between pre- and post-test were sustained at 1-month followup.
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Chapter 4. Results
Focus Group
Five people participated in the focus group, 3 women and 2 men. Two overarching
themes regarding PD symptoms were identified: (1) tremor and (2) planning. Discussion
regarding tremor had to do with the extent to which tremor affected daily living. Types of
tremor, such as Parkinson’s tremor, essential tremor, rocking tremor (a form of
Parkinson’s tremor), and whole body tremors were discussed.
The second theme involved activity planning. For example, participants discussed
how much planning was involved in any activity, whether it was getting up from a chair to
walk down the hallway, planning to go to dinner with friends, or going to get the mail.
Discussion around planning included any movement, such as where to place feet when
standing up from a chair, whether to use a cane or a walker, as well as more global activity
planning, such as arriving early in order to allow more time for getting into a building and
which invitations to accept or decline based on the energy level required to get there and
participate in the event. A summary of the narrative follows.
Participant 1 (P1) is retired from university teaching. He describes himself as quiet
and reserved, and his wife is active in the local PD family support network. Participant 2
(P2) is a university faculty member and is still working part-time. Her first sign of PD was
that her hand began to tremble when she was holding notes in class for her lecture. She is
active in the local PD support community. An important goal for her is to decrease the
stigma of PD. Participant 3 (P3) is retired from a university staff position. He was
diagnosed 4 years earlier, after he noticed he was “walking funny.” In hindsight, he realized
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that PD symptoms for a few years prior to that. Participant 4 (P4) was diagnosed 2 years
earlier and knew only about 8 months prior to her diagnosis that something was wrong.
Specifically, she noticed she was in a “permanent brain fog” when she was traveling at
Christmastime to visit a family member, and she had begun experiencing tremor. In the
year previous to the focus group, she developed gait hesitation (freezing of gait).
Participant 5 (P5) was diagnosed 2 years previously, and her diagnosis was a surprise to
her. She had a family history of benign tremor, and she thought that her own tremor was
like that of her relatives and nothing more. She was treating at a local pain clinic following
back surgery, and one of the staff members asked if she had ever been evaluated for PD and
referred her to a neurologist, where she was diagnosed. She is a retired computer systems
specialist. A key issue for her has to do with anxiety that she feels anytime she is out of her
home or away from her husband, who is her main support.
The key objective of the focus group was framed “to gain insight about how PD
patients would prioritize symptoms of the disease in terms of how much they interfere
with quality of life”. Questions were designed to elicit responses about how PD might
interfere with (1) day-to-day function on a regular basis (2) activities that occur routinely
but not daily (e.g., church, social activities, holidays).
In response to the first question about symptoms that get in the way on a regular
basis, P3 indicated “walking is the biggest problem”. He used a cane until the previous
summer but then his physical therapist told him he should be using a walker. While he feels
“a whole lot better with a walker” and that he can go more places with it, it gets in the way
when he has to turn around or do anything with his hands. He felt that he was “always
turning around” and figuring out how to maneuver with his walker.
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P4 indicated that “weather is a problem” for her because she still drives, lives in an
apartment building, and parks her car in an uncovered parking area (lot). It is not a long
walk for her to get to her car but brushing the snow off, with the risk of freezing of gait or
gait hesitation at any point, “makes me think twice about how I have to want to get out and
whether I can get a ride or whether there is enough time to clear off my car and things like
that; I always have to plan ahead.”
P2 said that her biggest issue “has been an increase in anxiety” stemming from “the
fact that I know I have to plan ahead; I have to plan how I dress because when its really
cold, my whole body goes into tremors.” She indicated that the whole body tremors were
the only issue that upsets her family, especially her husband and grandchildren. This
anxiety has been the cause of her “almost slowing down” to the point of giving up teaching.
However, student evaluations are still positive, and she feels she is still cognitively very
able, so she has kept going. She contributed that she has never before encountered
anything like the anxiety that “can take over your life” and be so “overpowering”. She stated
that she has an anti-anxiety prescription and is learning “how to deal with it”. Another
participant asked if it was like an anxiety attack, to which P2 said that it is not an attack but
that she gets “real anxious” and then it triggers an issue she has with her stomach, similar
to Crohn’s disease; she said that the issues with anxiety “go to her stomach”, which she has
had problems with her whole life. She attempts to calm down by breathing and
“concentrating on how to get it under control”. P2 also indicated that she has tremor
predominantly with her right hand.
P1 said “at the moment, my biggest problem is the side effects from the medicine I
took to help with what had been my biggest problem before I started taking the medicine”.
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The current issue this participant was referring to had to do with the drowsiness side effect
from a medication for tremor that was recently added to his protocol. He reported that he
has Parkinson’s tremor, which manifests for him as a rocking motion when he grasps
anything. This makes it difficult, if not impossible, for example, to drink from a water bottle
or coffee cup. In response, P2 said that she had the same issue with increased tremor when
grasping but less predominantly than P1. P1 added that symptoms and side effects are
varied and whichever one is causing the most difficulty at the time is the one on which you
are focused. P5 added that this is something “you fight everyday”.
P2 underscored the importance of the support of her husband, saying “knowing that
I’m not alone with this and that I live with someone who is so understanding and helpful” is
vital.
Participants noted how each person in the group had a different set of symptoms,
some of which are common among them and some of which are not. P1 commented that it
was “an advanced al la carte menu” and that whatever is “your worst symptom at this
moment” gets all of your attention. All agreed that it was difficult to sort out symptoms that
are related Parkinson’s, medication side effects, and normal aging. Everything gets
attributed to PD, when some symptoms are likely just normal aging. For example, P2
commented, “Does anyone else feel that it's sometimes confusing to know that it is
Parkinson’s or if its aging because at 75 I know that aging is setting in.” P2 also commented
that PD adds uncertainty to normal aging and planning, and planning becomes more
complicated. For example, she had cataract surgery recently, and being without the use of
one eye for a period of time was especially frightening for her. Therefore, she had to do
extra thinking ahead about how she would manage. P3 added that he compares himself to
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his brother who is 13 years older but does not have PD as a type of reality check regarding
what might be normal aging and what could be contributed to PD. P5 underscored her
anxiety anytime she is away from her husband: “we have been married 24 years; if
something happens to him, I don’t know what happens to me … the fear of being left alone
here without him … you never know from one day to the next …”.
Regarding fear, participants discussed the importance of self-talk and “talking your
way through” whatever is of concern at the moment. Participants also noted that
“Parkinson’s is the good disease to get” because you “die with Parkinson’s, not from it”. P3
noted that “there is not a sonic boom when we walk by” but “we are still around” and that
you have got to keep your sense of humor. P2 felt that her involvement in the PD support
group and Delay the Disease meetings helps her maintain a sense of humor and counteract
any depression that she begins to feel. P3 added that he and his wife will accomplish
something that should have been quick (but was not) and say to each other “look how easy
that was!” P4 noted that when she goes to the grocery store and gets back home, she feels
that was a great accomplishment for one day because she got what she needed, did not fall,
and interacted with people; she added that “you have to pat yourself on the back for the
small things”. P3 agreed that with PD, you can easily lose track of what you want to do each
day but even if you did one thing, such as pay a bill, you can “look back and say I did
something and the day wasn’t a waste; I accomplished something no matter how small it
is.”
When thinking about less routine activities over the longer-term, and PD issues that
get in the way of enjoying life, P2 indicated that she need to constantly remind herself that
her balance was off. Prior to her diagnosis, she would get a step stool and climb onto the
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counter to reach dishes on higher shelves. Her balance has improved significantly as a
result of exercise; however, she reported, “the biggest hurdle [in the longer timeframe] was
to understand that I had a balance problem”. P4 commented that getting caught in social
situations, and the anxiety this can provoke, has been difficult for her. The onset of her
anxiety can be sudden, making her “weepy and confused”. Two examples she cited were
when she drove with her sister to visit friends and when they arrived, the friends ran out
“screeching and yelling hello” and the dog started barking, and it was all overwhelming to
her. Her second example involved attending live events at a local auditorium, which has led
her to figure out that she needed to arrive early and avoid intermission in order to
circumvent the crowd, but then she needs to use the restroom after intermission and when
the event has resumed. She has a thought process that she has developed in order to calm
herself. Both participants 2 and 4 had determined their preferred seating at this venue so
that they can make a quick exit if needed. P4 added that anytime she travels where there
might be an escalator or door that opens and closes quickly or that revolves, she has to
think ahead and pad her time in order to get from point A to B on time. She said “you have
to think about the layout of their living room and how you get from point A to point B and, I
know a friend who is 95, and I can't go and see her anymore because I would have to park
in the street and then go up the driveway and her driveway is so narrow that the grass
grows right to the edge, and if were to get out, I would get out on grass and lumpy stuff and
her railing is very wobbly. So there are a lot of things like that I have to think about so I
have to plan to see her elsewhere.” She also said “it takes a lot of planning and
preparation”. P2 added that “it slows you down socially” and “takes away some of the social
freedoms we felt before”. She commented that before her diagnosis, she would not think
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twice about flying but now she has to plan a great deal more than before her diagnosis
before any type of travel. P1 commented that he always gets an aisle seat on a plane to
make getting in and out of the seat easier.
In response to being asking to think about the impact of PD in the longer-term, P3
commented that there are “little things that I used to be able to do that I can’t anymore; I
used to roll the garbage can out to the street … but now I have got to get back and I have my
walker [whereas before], I had my cane”. He further noted that winter seems worse
because of the weather. Prior to his diagnosis, he did all the grocery shopping, but he
cannot do that anymore, and even to “run out and get milk” creates issues of figuring out
how to manage picking up items while using his walker; therefore, he feels able to do less
and less. P4 noted that she chooses grocery stores that are quiet and will carry groceries to
the car for her. She also uses a backpack, which frees her hands to use her walking pole.
P4 noted that overtime, it is taxing to think about things like visiting a friend
“because you have to think about the layout of their living room and how you get from one
point to the next.” She has a friend she can no longer visit at her home because the walk up
to the house is uneven and the railing is not secure; therefore, she said “I have to plan to see
her elsewhere”. P5 added that she cannot even think about going out very much anymore.
She and her husband used to be square dancers but they had to give that up; she
commented, “you do lose a lot, you lose a life, you really do; I feel like I’ve lost my life ... its
gone”. P2 responded that the Delay the Disease class has helped her a lot, including that she
has not had to increase her medication in 3.5 years.
P3 noted the paradoxical functioning with PD; for example, he needs a walker yet he
can drive just fine. One way he has adapted is that he volunteers to do anything that
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involves driving and picking up without needing to get out of the car, such as prescriptions
and carryout.
P2 underscored the importance of exercise and Delay the Disease classes to her, to
which P3 responded that it is hard for him to get out in the winter because of his walker
and there is limited ability to exercise in his house. He has 3 walkers that he has “stationed”
in different places so they are where he needs them for different activities. He added that it
takes “pre-planning” to figure out which device one needs for different situations. He also
commented that he has reading glasses in several locations so he does not have to walk to
find a pair. Participants exchanged information about the car cane, which inserts into a
car’s door latch and provides a handle for assisting with exiting a car. P2 replied, “see how
creative we have become with planning!”
P1 responded, “Figuring anything out is more challenging. Just feel like my brain has
slowed down. It is hard to even put together a sentence. When you are trying to uh, like
now when I am trying to think of the right words I want to say, just takes an effort. But on
the other hand, another symptom that is common is apathy. It is almost like a saving grace
because if it is impossible for you to do stuff that you know you are used to doing, it kind of
helps to not care. You get depressed, you know. I have a train lying around too [P3 had
commented that he did as well] and I was sure that I was going to spend my old age
working and getting the cars working just right and getting the tracks .... you can't work
with your hands and so.... it is a separate syndrome, a symptom, that you do not care, and it
helps that you get to think of apathy as being beneficial. But the reality is that it is not all
bad.” P3 responded: “You get to the point where you say, ‘good enough’ … “I used to be able
to do this really better but today I got it done and that is good enough.”
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Participants had varying levels of comfort in talking to family members and others
about their PD. P5 commented that very few people, including family members know she
has PD, while P2 discussed having a feeling of obligation to talk about her PD in order to
decrease the stigma. P3 at times feels he needs to let people know, for example, while
waiting in line, because he moves more slowly than others. He added that even strangers
had been “very, very nice” and that he had met a lot of wonderful people through talking
about his PD. This discussion led P3 to share that a big fear of his is getting halfway to
where he is going and not being able to continue, or go to a performance or activity where
he is seated and not being able to get back up. P4 indicated that PD makes her feel selfconscious, for example, if she holds up an elevator. P2 responded “I was given this disease
and now I have to do something positive from it. I have to say it proudly, I'm not ashamed
of it, I did not do anything to hurt anyone for it to happen to me, it just happened for a
reason and that's the only way I can survive …” P5 responded that she felt she had lost part
of her uniqueness and part of herself. P2 underscored the importance of helping people
“combat … feeling less about themselves …”. The focus group ended with P2 reiterating the
importance of helping people “conquer those fears”, to which P3 responded “you have to
keep yourself going and [not let] the bad side take over.”
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Focus Group Summary
While participants touched on many aspects of PD, analysis revealed that, of all the
issues discussed, the only 2 issues that all participants indicated were troublesome were
tremor and the need to plan activity regardless of the simplicity or complexity involved,
and this differed significantly than before the PD diagnosis. While everyone needs to plan
(e.g., for travel), participants indicated the consciousness related to planning now required
due to the PD diagnosis, as well as how essential contingency planning had become. The
need to plan was not discussed as a symptom per se but rather as an added burden to every
activity. Also, tremor and planning were among the top mentions of any topic, with tremor
having 32 mentions and planning having 35 mentions. Tremor was important because it
directly affected each participant, though it manifested differently for each person. In
contrast, only 3 participants mentioned balance and gait, which are also highly associated
with PD. Discussion about planning was woven throughout the focus group as a type of
added burden to the disease, rather than a direct symptom of PD. Based on the results of
the focus group, a pilot study was designed that included 2 protocols, one to attempt to
address tremor and one to address planning. Table 6 summarizes issue mentions.
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Table 6. Focus group issues and mentions by number of participants.
Themes
COGNITION
Plan, planning, figure, figure out, think
ahead, think about, learn
PHYSICAL
Tremor, shake, shaking
Walking, walk, mobility, balance,
balance, gait, walker, cane, stand
Constipation
Pain
Sexual dysfunction
MENTAL HEALTH
Depression, alone, feeling alone
Anxiety, fear, afraid, loss of control
OTHER
Side effects
Changing symptoms
Family, social impact, social freedom

Number of
mentions

Number of
participants

32

5

35
41

5
3

3
8
3

3
3
2

12
46

3
3

2
11
4

1
3
2
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Neurofeedback Pilot Study
Participant characteristics are provided as Table 7. All participants were mid-stage
Parkinson’s, characterized by bilateral disease, and mild to moderate disability but physical
independence (Goetz, Poewe, & Rascol, et al., 2004). People with previous NFB or deep
brain stimulation implants were excluded, and participants had to have a confirmed PD
diagnosis. Participants were 66-75, 2 female, and 1 male, and they had key issues of tremor,
anxiety, and freezing, and they were 2-5 years since diagnosis. Participants were randomly
assigned to the intervention groups, while the control person requested assignment based
on convenience.
Table 7. Pilot study participant characteristics.
Group

Age

Gender Key Issues

1 SM

75

F

2 SM+Cog
3 Control

66
73

F
M

Essential tremor,
Anxiety
Freezing of Gait
Rocking tremor

Employment Years from
Diagnosis
Part-time
3
No
No

2
5

QEEG Results
SM Condition. Figure 2 shows the brain map results for the person who received the
SM condition. The map shows Z scores to indicate the number of standard deviations
between the mean amplitude of each band (delta, theta, and so on) compared to normative
databases. Normal is shown as green, deficiency as shades of blue, and excess is shown
progressively as yellow, orange and red. The color legend is provided below each set of
maps. The top row shows the pre-test, while the bottom shows the post-test.
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Theta and high beta were decreased (i.e., were more normalized) at post-test.
Importantly, Z scores fell two standard deviations, from four to two.
Figure 2. SM condition pre/post QEEG results.

SM+Cog Condition. For the SM+Cog protocol, changes can be noted across the bands, with
improvements in frontal delta and theta, central alpha, frontal beta, and frontal and central
high beta, as shown in Figure 3.
Figure 3. SM+Cog condition pre/post QEEG results.
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Control Condition. Results for the person in the control condition are provided as
Figure 4. Here, we see some apparent declines at posttest in delta, beta, and high beta.
Figure 4. Control condition pre/post QEEG results.

Disability Percentage and QOL Results
Between pre- and post-test, the overall percent disability decreased 36% (from
10.6% to 6.8%) for the person in the SM condition, which was the most for any group. This
person also reported the least pre-intervention disability. This participant reported a
further disability decrease of 38% at the 1-month followup (from 6.8 to 4.2%), for a total
disability decrease of 60% between the pre-test and the 1-month followup.
The person in the SM+Cog condition reported a 12% disability decline (from 14.8 to
12.9%) between pre- and post-test, while at the 1-month followup, this participant
reported a slight increase in disability to 13.7%, for an overall decrease of 7% between pretest and followup.
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The person who served as the control reported a slight disability increases between
pre- and posttests and again between posttest and followup, for an overall increase of 25%
(from 16.3% to 20.5%). These results are provided in Figure 5.
Figure 5. WHODAS overall disability percentages by treatment condition.
25.00%
20.00%
15.00%
Pretest
Posttest

10.00%

1-Month
5.00%
0.00%
Sensory Motor

Sensory Motor +
Cognition

Control

In terms of the 6 component WHODAS domains, participants reported the following
results:
Cognition: The person in the SM condition reported a 50% disability decrease (from
8 to 4%), the person in the SM+Cog condition reported no problems at either time point,
and the control person reported a 25% disability decrease (from 33 to 25%).
Mobility: The person in the SM+Cog group, who had freezing, showed a 10%
decreased disability (from 45 to 40%). There were no changes in the other two groups.
Self care: There was no change in any group.
Getting along: The control person reported a 100% worsening (from 10 to 20%).
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Life activities: The person in the SM condition reported a 33% decrease in disability
(from 9 to 6%), while the SM+Cog person reported no change and the control group person
reported a 33% worsening (from 9 to 12%).
Participation: People in both treatment conditions reported improvements on this
domain, while the control person’s score was unchanged. The person in the SM condition
reported a 59% decreased disability (from 22 to 9%), while the person in the SM+Cog
group reported a 12% decrease (from 25 to 22%).
Anecdotal Reports
In terms of anecdotal information: In sessions 1-4, the person in the SM condition
reported improvement in tremor, even when she was hungry and tired. In sessions 5-8, she
reported that her tremor, usually visible by evening was less at that time now, and in
sessions 9-12, she reported that during a workout, she was better able to stand on 1 foot,
and she noted a possible improvement in anxiety, and that her “neck pain has decreased,
perhaps related to anxiety reduction”.
For the person in the SM+Cog condition, reports in sessions 1-4 included
improvements in freezing. During sessions 5-8, she reported improved sleep, further
improvements in freezing, and an “overwhelming sense of calm” and “well-being”. By the
final sessions, she had walked from her car to front door twice without freezing, and she
could not remember the last time she was able to do that. Also, when grocery shopping, she
noted being extra focused, without extraneous thinking, and she returned home within 1
hour, which was a short time for her.
Table 8 provides a summary of findings. Note that decreases indicate improvement
(less disability) and conversely, increases indicate declines (more disability).
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Table 8. Pilot study summary by group assignment.
Group

Key
Complaint

Map

Improvements
(Anecdotal)

Tremor
Anxiety

Improved
central
theta,
high beta,
SD

Tremor
Balance
Anxiety
Neck pain

2 SM+Cog

Freezing

3 Control

Rocking
tremor

Improved
frontal &
central all
bands,
theta SD
Declines
delta,
beta, high
beta
(unclear)

1

SM

Specific
Domains
% Disability
-50% cognition
-33% life
activities
-59%
participation

Overall
%
Disability
-53.8%

Freezing
Focus
“Calm”
Sleep

-10% mobility
-12%
participation

-7.6%

--

-25% cognition
+50% getting
along
+33% life
activities

+28.4%

Research Questions
To answer the first research question, 12 NFB sessions appear to successfully
demonstrate improvements with mid-stage Parkinson Disease. Positive changes were
observed in QEEG maps, QOL measures, and anecdotal information. Based on anecdotal
information, participants began to notice changes as early as session 4 of the intervention.
For the second question, changes appear to be enough to improve QOL indicators, in
general. The people receiving either intervention showed an improvement in overall QOL
scores.
Related to the third question, the people in both intervention groups reported
improvements both on the WHODAS and anecdotally. The greatest decrease in disability
for either intervention group was participation in society, which includes issues such as
“problems with barriers, living with dignity, and being emotionally affected by your health
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condition.” The person in the SM condition additionally reported improvements in
cognition and life activities, and the person in the SM+Cog condition additionally reported
an improvement in mobility, as well as improvement in cognition – the extra focus – though
this was anecdotal.
In summary, results of the pilot study showed the following:
Brain Mapping
x

Some consistency in type of brain disregulation across participants was noted;
however, variations were also noted, though all participants were within the same
disease stage (mid-stage).

Pilot Results Summary
x

12 sessions of NFB was sufficient to demonstrate changes in QOL using the WHODAS
(main outcome measure).

x

The tremor measure tested did not produce reliable results.

x

The person who reported the least disability pre-intervention showed the most postintervention improvement.

x

People in both treatment groups indicated a notable improvement on the WHODAS
participation in society domain.

x

Participant observations were important in understanding the results.

x

Sham NFB for the control group or additional baseline measures for all participants
should be used to strengthen the validity of conclusions.
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Neurofeedback Intervention Study
Final design modification based on the pilot study included the following:
x

Measures: Use WHODAS cognition sub-measure to assess changes related to NFB
training at FP1; use the Unified Parkinson’s Disease Rating Scale (UPDRS) patient
questionnaire item for tremor to assess any changes related to NFB training at C3 and
C4; drop the tremor app measure. Add formal component for participants to report any
changes they note that may not be captured in the written surveys.

x

Participants: Based on brain map results and differences noted for participants within
the same disease stage, drop the attempt to include only mid-stage Parkinson patients.

x

Design: Use a single subject design and compare participants’ post-intervention and
followup scores to their own pretest scores. Improve comparability between pre-test
and post-test results by adding two baseline EEG measures prior to the intervention.
Simplify design and interpretation by including one protocol that includes both C3/C4
and FP1 in the intervention. Inclusion criteria were (1) Confirmed PD diagnosis (2) No
DBS implant (3) No significant comorbidity and (4) no previous NFB treatment.

Participants
Participants completing the intervention were 6 males and 1 female and an average
of 4.9 years since diagnosis (range 1.5 – 6.5). Their mean age was 67.8 (range 59-80), and
they had key issues of unilateral tremor, soft voice, word-finding, brain fog, balance, sleep
problems, drooling, dystonia, weakness, fatigue and short-term memory loss. One person
worked full-time, 2 had regular volunteer or part-time work (< 5 hours per week), and all
others did not work or regularly volunteer. Table 9 provides characteristics of the
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intervention participants ordered according to years since diagnosis and then age.
Participants A-G completed the intervention. Participant H began the study but dropped
out after session 3 due to the time commitment required and conflicts with a number of
other appointments he needed to schedule. The average number of days for completing the
20 NFB sessions was 33.4 (range 19-48).
Table 9. Intervention participant characteristics.
Issue Report
ID

Years
since
dx

Age

Sex

Surgical, other
history

Work,
volunteer
hours per
week
0

Walk
aid

Tremor

Cognition

A

1.5

59

F

--

No

X

--

B

1.5

66

M

Ruptured
colon,
concussion
--

<5

No

X

--

C

3.5

67

M

0

No

X

X

D

4.5

66

M

Knee
replacement
(1), face
reconstruction
due to injury,
plate inserted,
concussion

40

No

X

X

E

6.5

68

M

0

No

X

X

6.5

69

M

Pacemaker,
ACL repair,
diabetes
Knee
replacement
(2), prostate,
Achilles
tendon (2)

F

<5

Yes

X

X

G

6.5

80

M

Parent had
non-PD tremor

<5

No

X

--

H

10

78

M

Heart attack,
stints (twice),
back surgery,
adult-onset
asthma

No

No

X

X
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Qualitative Reports
Qualitative reports for each of the 7 participants are provided to document changes
participants noticed during the intervention and demonstrate the variation in individual
response.
Participant A had chief PD symptoms of fatigue and mild left-side tremor. She
reported no significant personal or family history related to PD, and she is no longer
working.
At Session (S) 11, this participant said that over the previous weekend her husband
commented that she seemed to be doing better. She reported that she felt good over the
weekend but it was hard to pinpoint anything specific. At S17 she reported that she had
some better days regarding tremor since beginning the study but also some days that
seemed worse.
Participant B reported key symptoms of communication problems and “coming
across the wrong way” and right-side issues of leg tremor, arm stiffness, and hand tremor.
At S2 he reported that he felt more calm and had a slight headache after the
previous session. At S3 he reported that he felt even more calm and that his tremor may be
a little better. At S5 he said that he continues to feel increasingly calm. At S7 he said that he
has noticed subtle changes that are hard to precisely identify; he feels better and continues
to feel calm. At S10, he felt that his right-leg tremor was improved. At S15, he reported
continued improvement in tremor and indicated that hand tremor has not been noticeable
and that leg tremor is also improved. At S16, he said that he seems to be “thinking more
clearly, the cobb webs are clearing out”, and that he was “remembering things better”. He
had a slight headache after the previous session that went away without medication. At
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S17, he indicated that at times, the hand and leg tremor are gone and that the remaining
tremor is in his right foot. He had a very mild headache after the previous session that went
away without medication. At S18 he said that he continues to “just feel better” and that he
reduced his dose of Sinemet yesterday from 3 to 2 pills per day. At the 1-month followup
session, he indicated that the tremor improvement and overall “feeling better” has
continued to improve since the posttest, and that his wife has noticed the changes and
agrees. His right leg and foot tremor have improved and at times, he has no tremor at all.
He has noticed that if he gets anxious, his right leg tremor increases. He also indicated that
he continues to remember things better.
Participant C reported symptoms of left-side hand tremor, drooling, short-term
memory issues, and mild balance problems. At S2 and S6, he reported that he was mildly
fatigued after his sessions. At S12 he said that his balance and light-headedness on standing
may be improving. At the posttest session, he reported that he can now tap both hands
without his left hand beginning to tremor. Previously when he did this, his left hand would
start to tremor. He can also move his hands per an exercise class movement (waving his
hands in the air in front of him) without his left hand beginning to tremor. At the 1-month
followup he reported that his sense of smell has been better, though not consistently. His
sense of taste may also have improved, but again it is not consistent. His tremor seems
about the same, and mild right-side tremor has begun. His back pain has been worse, and
he noted that exercise makes it worse but it is recommended that he continue his current
exercise routine.
Participant D had chief PD symptoms that included bilateral tremor, soft voice and
word-finding. He was hit in the face with a baseball in his 40’s, which resulted in a serious
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concussion and the need to have reconstructive surgery and an implant on one side of his
face. He has also had knee replacement. His chief improvement involved improved
cognitive ability, including word-finding, memory, and the ability to continue talking and
holding his thoughts in spite of tremor.
At session 3 (S3), he noted that he was “possibly thinking more clearly.” At S4, he
said that he was “grasping words better” and at an earlier doctor’s appointment that day,
he could remember all of the questions he wanted to ask, which he could not previously do
with confidence. At S8 he felt that word-finding continued to improve. At S10 he reported
that a colleague told him he was “mentally sharper and remembering things better”. At S12,
his tremor seemed a little worse to him (bilateral instead of unilateral) the last couple of
days but he was still able to hold a train of thought and keep talking in spite of tremor.
Previously, increased tremor led to increased issues of word-finding, soft voice, and speech
fluency.
At S13, he reported continued improvements in his “brain working better” and
better ability to think and speak in spite of tremor. He had stopped taking propranolol, a
drug used for tremor, prior to beginning the intervention due to having surgery, and at S15,
he reported that he began taking the drug again.
At the followup session, he reported that he had some regression since finishing the
intervention, including the improvements he had gained in the ability to continue speaking
and holding his train of thought in spite of tremor. Also, he had fallen at the gym 2 weeks
earlier when doing an exercise involving running backwards.
Participant E had chief symptoms of tremor, predominantly in his left hand,
problems getting to sleep due to tremor, and mild balance issues. Sinemet and other
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medications for tremor have been ineffective for him; therefore, he does not take them. He
had ACL repair several years ago, and he is diabetic. He also received a pacemaker a few
months prior to the intervention.
At S2, he reported that he was fatigued after the previous session. At S5, he reported
that he had a particularly good day the previous day. At S7, he had gotten his driver’s
license back; he had not driven since he had the pacemaker because prior to the
pacemaker, he had fainted a few times. At S18 he reported that his wife noted he seems
more alert. At the followup appointment, he had not noticed further changes.
Participant F had chief PD symptoms of right-side tremor, especially in his hand,
balance, and bilateral palsy. Significant medical history includes double knee replacement,
Achilles tendon surgery (both sides) and prostate surgery.
At S2, he reported that the evening following S1 he noticed more details at home,
had “better ability to focus” and that he had not realized what he was missing [in
conversation at home]. At S3, he reported that he was “better able to think about how to get
back on track” when he loses focus. At S4, he indicated that his brain fog was improving,
and that it was normally like “looking through a mirror or window with soapy film on it
and the film is beginning to clear away.” At S6 he noted that he has felt fatigued following
sessions. At S7, he said he has continued to feel fatigued following sessions but that he feels
his focus is improved. At S8, he said he feels his balance may be a little worse but that he
had forgotten to take his mid-day medication dose today and that he missed 2 doses the
previous day, or took them late.
This participant continued to report fatigue at S9 and that he was going to bed about
2 hours earlier than usual. He takes 10 mg melatonin and a prescription sleep aid. He is
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sleeping 9-10 hours instead of his previous 7-8. At S10, he reported that tremor seems
stable. At S11 and S12, he noted that he has not attended his exercise class the last 2 weeks
due to the weather and feels his balance is off due to this and that the extremely cold
weather may be affecting his knee replacements and therefore, his balance.
He reported more fatigue than usual S13, as well as that he napped the previous day
late in the day and still went to bed at 9:30 pm, and that the earlier improvements he noted
in focus have held. At S17, he reported that he had gotten up in the middle of the night and
when trying to get up, slid down the bed and onto the floor; his wife was able to help him
get back up. At S18, pain had increased, making it more difficult to rise from a seated
position. At S19, he was fatigued at the beginning of the session, which was later in the day
than usual. At S20, he reported that he went to a concert at church the previous Sunday and
a friend noted that he did not shake during the entire concert, which was significantly
different than before the intervention. He is also feeling better today and slept from about
11-7; he feels that his stability and walking are better.
At the followup session, he reported that he feels his tremor is about the same as
when he ended the intervention and that his “focus does seems better”, though he is still
forgetful, and he noted that it is hard to tell the difference between PD symptoms and
normal aging.
Participant G had chief PD symptoms of bilateral hand tremor and occasional
balance issues, with no significant personal or family history related to PD. He is diagnosed
with restless leg syndrome (RLS). Notable improvements he mentioned during the
intervention were less tremor and better sleep quality. At S2, he indicated that his tremor
has been worse the last couple of weeks, including increased tremor at rest. After S1 (the
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previous day), his tremor was notably better and he had no tremor at rest. At S3, he
indicated that he usually wakes one or more times per night for an hour or more each time,
and that the previous night (following S2), he “had a great night’s sleep.” In addition to
continued improvements in sleep, at S4, he reported improvements in tremor, including
while brushing his teeth, and that during the C3, C4 protocol that day (S4), his tremor at
rest improved. At S6 he noted he had gained 3-4 pounds since beginning the intervention,
which he indicated that he wanted to do. Over sessions 8-9, he noted continued improved
sleep and that he was trying to take medications at the same time every day, which had
been a challenge for him (e.g., leaving the house in the morning and forgetting to take his
afternoon medications with him). He also noted at S8 that he no longer needed an
afternoon nap.
At S10, he said that his wife noticed 2-3 days previously that he was not moving
around as much at night due to restless leg syndrome (RLS). On the way to the session that
day he began to get nervous due to the slippery roads but was quickly able to calm down.
At S11, he felt that his tremor was improved at times but at other times, he felt it may be
worse. However, at S12, he noted that on Sunday he was better able to hold a hymnal with
one hand and with either hand, and that his sleep and RLS remain improved. At S13 he
noted that he had an easier time drinking coffee that morning but a harder time brushing
his teeth. At S14, he noted that he was up later than usual the night before so he thought he
would be fatigued this morning, but he was not.
At S15, he reported that while doing a home project last night involving using an
electric drill to do a ceiling repair, he could hold the drill over his head with one hand, and
he was able to use a screwdriver with one hand and could get it into the screw head easily.
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Previously, he would have needed to use both hands for either task. He could hold his
coffee cup better this morning, his hand would tremble then stop, whereas previously, it
would begin to tremble and not stop. He was up once the previous night for 1.5 hours. At
S17, he reported some regression in tremor over the previous weekend and that he had not
slept well the past 2 nights.
At S18, he reported overall improvements in tremor, with some regression, and that
at the beginning of the intervention he had tremor “100% of the time” when brushing his
teeth or drinking from a cup. He now has “at least 50% improvement”. He can brush his
teeth 50% of the time without tremor and can grasp the handle of a cup normally, whereas
before he had learned a specific way to grasp a cup handle that helped with tremor, and he
had to use 2 hands. Recently, he has been able to “grasp a cup normally” and use one hand.
At S19, he reported that he combines a thought process with the new improvements in
tremor in which he thinks “stop shaking” or “hold”, which seems to help. At S20 he noted
that he had one-third success for brushing his teeth the last few days, that holding a cup
remains improved, and that his sleep the last few nights was “excellent”.
At the followup session, he said that tremor had remained improved until the
previous week. He has been anxious due to an upcoming 3-week trip and believes the
anxiety made tremor worse. Sleep and RLS remained improved. He is sleeping 7 – 7.5 hours
per night without waking. He feels he no longer has RLS; he has leg pain but he no longer
feels the need to move his legs, as he did prior to the intervention. He has noticed that
toothbrushing is better at night than in the morning and holding a coffee cup has remained
improved.
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Tremor Scores
Tremor scores for each participant at pretest, posttest, and followup are shown in
Figure 6. From the graph we see that all participants reported at least a minimum level of
tremor at pretest, and that pretest tremor scores are generally worse as the years since
diagnosis increase across participants A-G. We also observe that reported tremor scores
worsened at posttest for participants B and C before returning to pretest levels at followup.
Scores for participants A and D were unchanged across measurement timepoints.
Improvement was noted at posttest for participants E, F, and G, all of whom were
diagnosed 6.5 years prior to the intervention. This improvement held at followup for
participants E and G but returned to pretest levels for participant F.
Magnitude of change. Any reported change in either direction was one point
between measurement periods.
Figure 6. Tremor scores by participant.
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The EEG bands that were included in the protocols are provided in Table 10, along
with their normalized (expected) amplitudes for adults and a brief description.
Table 10. Training bands, normalized amplitudes, and descriptions.
Band
Theta
SMR
Beta
High beta

Normalized
amplitude
8.0 - 12.0
4.0 - 6.0
3.5 - 4.5
2.5 - 4.0

Description
Drowsy, state between awake and asleep, meditative
Relaxed but alert
Active attention
Hyper-alert, anxious, tense angry, agitated

EEG Results at C3 and C4
The following bands were down-trained at the training sites C3 and C4, which were
treated to attempt to improve tremor: theta (4-7 hertz) and high beta (22-36 hertz). SMR
(12-15 hertz) was up-trained at C4, while Beta (15-18 hertz) was up-trained at C3.
The EEG results show different patterns for participants based on reported
quantitative scores, as shown in the graphs below. Amplitudes are on the Y axis and each
measurement period is on the X axis. Because theta and high beta were down-trained, we
expect those lines to decline at posttest, and because SMR/beta were uptrained, we expect
that line to increase at posttest.
Figure 7 shows the C3 EEG for those who reported an improved quantitative tremor
score at posttest, which includes participants E, F, and G, all of whom were diagnosed 6.5
years prior to the intervention. The data show desirable declines in theta and high beta
amplitudes at posttest, but also a modest undesirable decrease in beta. We also observe
that high beta and beta lines are in reverse order, with a larger amplitude of high beta than
beta, and we see a trend in theta toward baseline at the followup.
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Figure 7. C3 EEG amplitude, tremor score improved at posttest.
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Figure 8 shows results for the 2 participants (B and C) who had verbal reports of
tremor improvement but not an improved quantitative score, Here, we see that high beta is
especially elevated and has the largest amplitude of any band but that high beta declines at
followup.
Figure 8. C3 EEG amplitude, tremor improved per verbal report.
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Followup

Figure 9 shows participants A and D, who reported no tremor change across
measurements and had no verbal report of change. We see from this graph that these
participants showed elevated theta compared to other groups and that bands were
generally stable across measurements, except for the decline in theta at followup.
Figure 9. C3 EEG amplitude, no tremor change.
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A similar pattern was observed with the EEG results for C4, shown in graphs 10-12.
Graph 10 includes participants E, F and G; Graph 11 includes participants B and C, and
Graph 12 includes participants A and D.
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Figure 10. C4 EEG amplitude, tremor score improved at posttest.
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Figure 11. C4 EEG amplitude, tremor improved per verbal report.
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Followup

Figure 12. C4 EEG amplitudes, no tremor change.
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Cognition Scores
Figure 13 shows cognition scores (percent disability) at pretest, posttest, and
followup by participant. The range of disability percentage was 0-25% at pretest.
Participants C, D, E, and G reported improvements at posttest, with decreased effect (i.e.,
increased disability) reported at followup. Participant A reported zero disability at all 3
timepoints, participant B reported an initial increase at posttest, with a decrease
(improvement) between the pretest and followup scores, and participant F reported
increases from pretest at both posttest and followup.
Magnitude of change. Score decreases for the group reporting improvement at
posttest were 4.2-8.3%, while the improvement for participant B between pretest and
followup was 12.5% and the decline between pretest and followup for participant F was
8.3%.
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Figure 13. Cognition scores by participant.
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EEG Results at FP1
EEG results at FP1, which was treated to improve cognition, showed desirable
decreases in high beta at posttest for the group reporting improvement at posttest, with a
modest increase in high beta at followup. Beta was modestly decreased at posttest
(undesirable), which was unchanged at followup. Theta was unchanged across
measurement periods. These results applied to participants C, D, E, and G and are
represented in Figure 14.
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Figure 14. FP1 EEG amplitude, cognitive score improved at posttest.
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As shown in Figure 15, Participant B, who reported improvement at followup, had
decreases in high beta at posttest and again at followup, with a comparatively elevated high
beta at pretest; he also had a modest decrease in theta at posttest followed by a small
increase at followup, and small decreases in beta at posttest and again at followup.
Figure 15. FP1 EEG amplitude, cognitive score improved at followup.
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Followup

Participant A, who reported no change across measurements showed stable EEG
results between pretest and posttest, with declines in theta (desirable) and beta
(undesirable) at followup, as shown in Figure 16.
Figure 16. FP1 EEG amplitude, no change in cognitive score or verbal report.
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Participant F, who reported a worsened cognitive score at posttest but
improvement based on verbal report, had declines across bands at posttest with increases
at followup, as shown in Figure 17.
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Figure 17. FP1 EEG amplitude, worsened cognitive score, improved per verbal
report.
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Combined results for tremor and cognition scores and qualitative reports are
summarized in Table 11. Only participant G, who was 6.5 years post-diagnosis and the
oldest participant, had improvements in both the tremor and cognition quantitative
measures that were sustained at followup; the cognition score (i.e., disability) increased at
followup but not to the baseline level.
From the qualitative reports summarized in the final column of Table 11, we see
that only participant A, who was the youngest and 1 of 2 most recently diagnosed
participants, did not notice a great deal of change during or following the intervention. She
was also the only female participant.
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Table 11. Combined results by years since diagnosis and age.
Score Change
ID

Dx
Years

Age

Tremor

Cognition

Qualitative
Report

Pre

Post

1-Mo

Pre

Post

1-Mo

A

1.5

59

1

1

1

0

0

0

--

B

1.5

66

1

2

1

21%

25%

8%

C

3.5

67

1

2

1

25%

21%

42%

D

4.5

66

2

2

2

17%

12.5%

17%

Calm, tremor,
thinking,
memory
Tremor, sense of
smell
Word-finding,
memory,
speaking in spite
of tremor

E

6.5

68

3

2

2

17%

12.5%

25%

More alert

F

6.5

69

2

1

2

4%

26%

12.5%

Focus, tremor,
walking

G

6.5

80

3

2

2

8%

0%

4%

Tremor, calm,
energy, sleep
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Chapter 5. Discussion and Conclusions
This was a multi-stage study designed to ascertain symptoms that patients identity
as most significant that can be addressed using NFB, to pilot test NFB protocols to address
those symptoms, and to then conduct a larger intervention study.

Focus Group
The chief research question for the focus group was “How do Parkinson’s Disease
patients prioritize challenges resulting from PD?” The only issues identified by all focus
group participants were tremor and planning. Similar to previous studies, participants
discussed a wide range of issues. However, unlike other studies, participants explicitly
discussed the challenge of planning, and this was woven throughout the discussion.
Strengths of the focus group were beginning the overall study with a component to ask PD
patients their priorities in order to tailor the intervention to the identified priorities.
Limitations include conducting just a single focus group. Recommendations include using a
qualitative component in research design to develop intervention protocols with practical
significance to patients and conducting similar focus groups with a broader population of
PD patients, such as groups for those in the different stages of disease.

Neurofeedback Pilot Study
The pilot study was designed to determine the feasibility of the full study and to
answer the following research questions:
x

Can improvements to the QEEG be observed with mid-stage Parkinson patients with
relatively few neurofeedback sessions?
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x

Is there an association between NFB treatment and QOL scores?

x

Can changes in QOL scores be associated with specific NFB protocols?
The results were similar to previous work that showed specific types of

disregulation in Parkinson patients, specifically high theta and too little beta. Findings were
consistent with research showing positive results in few sessions. Unlike other studies,
multiple symptom treatment and QOL measures were included. The pilot was useful in
testing QOL and tremor measures.
Anecdotal information was important in understanding the results, and the study
showed that selectively targeting motor and cognitive issues may result in specific,
differential outcomes. Adding multiple baseline measures or a sham condition to blind all
participants to the treatment they receive would strengthen findings.
Participants in both treatment conditions improved, while the control person did
not. However, the person who reported the most improvement also reported the least
disability at pretest. This indicates that the extent of change may depend on level and
perhaps type of pre-treatment impairment, even within a given disease stage. This
participant was also the oldest of the pretest cohort.
Strengths of the pilot study include a multi-dimensional treatment approach for
treating PD with neurofeedback and inclusion of QOL measures to assess changes in
various domains of functioning. Limitations include challenges in obtaining a truly
homogeneous sample, pilot data with just three participants, and lack of random
assignment for the control condition. Also, obtaining brain maps at just two points in time
(pre- and post-intervention) does not provide interim results that might show a trend, or
that might help explain changes observed. A final limitation is the placebo effect; that is,
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participants knew they were receiving treatment, and therefore, may have over-reported
improvements (the anecdotal information), and they may have guessed that treatment
would target motor symptoms.
Recommendations resulting from the pilot include using only the cognition domain
of the WHODAS and the PQ tremor question as the outcome variables and incorporating a
diary or qualitative component to capture what study participants noticed during and
following the intervention.

Neurofeedback Intervention Study
The NFB intervention component of the study was designed to determine whether
self-reported tremor and cognition scores improve following 20 NFB sessions, whether any
changes are noted 1-month post-treatment, what changes participants notice during and
following treatment in addition to quantitative measurements, and how the EEG is changed
following treatment. Research questions and a summary of results were as follows:
x

Do tremor scores improve following NFB treatment? How do tremor scores change 1month post-treatment? Tremor scores improved at posttest for the 3 participants
who were 6.5 years away from diagnosis. This improvement held at the 1-month
followup for 2 participants but not for the other participant. The change in any
direction for any participant was a one point (on a 5-point scale).

x

Do cognition scores improve following NFB treatment? How do cognition scores
change 1-month post-treatment? Cognition scores improved at posttest for 4 of the 7
participants and for an additional participant at followup. Of the 4 participants who
reported improvement at posttest, cognition scores returned to pretest levels or
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worsened at the 1-month followup for 3 participants and also worsened for the 4th
participant, but not back to pretest levels. Overall, changes were modest except for
one participant (B), whose pretest EEG indicated particularly elevated high beta.
x

What qualitative changes, if any, do participants report during and 1 month following
neurofeedback treatment? Verbal reports by 4 of the 7 participants indicated
improvements in tremor. In all, 5 participants reported tremor improvements in
quantitative or qualitative reports. 5 participants noted cognitive improvements
and a 6th participant provided verbal report of improved cognition but did not have
an improved quantitative score. Qualitative reports documented improvement
during and following the intervention in motor symptoms that included tremor and
balance, cognitive symptoms that included memory, focus, word-finding, and
holding a train of thought in spite of tremor, and other symptoms that included
sleep, RLS, anxiety/agitation, fatigue, and light-headedness upon standing.

x

How does the EEG pattern at sites treated for tremor and cognition change following
NFB treatment? Are any changes sustained 1 month post-treatment? At C3 and C4,
participants reporting improvement were successful at reducing theta and high beta
but not at increasing beta. At FP1, participants were especially effective at reducing
high beta. The EEG at the 1-month followup was generally improved from pretest
but not to the extent observed at posttest.
Similar to a study by Erickson, et al. (2012), qualitative reports from participants

indicated positive change. However, changes in the Erickson study did not reach statistical
significance and in the current study, results were inconsistent and any changes were
generally modest. Unlike Azarpaikan, et al. (2014), this study attempted to change self-
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reported measures, rather than objective measures and included PD patients with varying
levels of affectedness from PD.

Strengths and Limitations
Strengths of the study include an attempt to treat multiple PD symptoms
simultaneously and to assess results using quantitative and qualitative measures. The 1month followup provided a glimpse of the impact of neurofeedback after sessions ended.
Limitations include a relatively small sample size and the lack of more precise measures of
tremor and cognition.

Research Recommendations
Future research should focus on a larger intervention study. Due to the time
required to conduct NFB (about 30 hours per participant for the current study), this would
likely require a multi-site intervention with practitioners using the same equipment.
Prevention is difficult to measure (Galea, 2015). For all study participants but
especially those who reported less impact by PD at pretest, and therefore had little room
for improvement at subsequent measurement time points, it is unknown whether any
benefit from NFB will be realized in terms of delayed symptoms and need for medication.
Future studies should include longer followup to help determine this. Case review could be
utilized in order to ascertain the need for medication for those receiving NFB compared to
a match set of controls. Several additional recommendations related to design resulted
from the study, as follows.
x

Measures. Objective and more precise tremor and cognition measures may
result in stronger documentation of changes. It is possible that objective
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measures of symptoms (e.g., time required to complete dexterity tests,
neuropsychology tests), rather than subjective self-report, would produce an
improved understanding of results. As noted in the literature (e.g., Dauwerse,
et al., 2014), as well as the focus group for the current study, symptom
comorbidity in PD is extensive. As demonstrated in the pilot study, EEG
dysregulation can manifest quite differently, even for PD patients in the same
disease stage. Azarpaikan et al. (2014) showed statistically significant results
with early stage PD participants using eight 30-minute NFB sessions and
objective measures of balance and gait. It is possible that more general
measures of symptoms and disability, such as were used in the current study,
are not precise enough to capture changes. Also, the confluence of symptoms
may make it difficult for participants to notice improvements in one
symptom when other symptoms worsen, injury occurs, or life events cause
stress. Changes unrelated or co-related to PD make interpretation of results
challenging.
Objective and more precise tremor and cognition measures may result in
stronger documentation of changes. Self-report has been shown to be
correlated to clinical assessment, therefore, the development of a more
detailed quantitative tremor measure that includes the different tremor
types (at rest, postural, and action) and a more refined scale (e.g., 10 point)
may more accurately capture changes and lead to better correlation between
qualitative and quantitative measures. It would also be useful to conduct the
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self-reported questionnaires at the mid-way point in the intervention to
attempt to show trends.
x

Recruitment. Extensive recruitment efforts were carried out and included
contacting local neurologists and PD support groups, as well as using
Facebook ads targeted to groups related to PD. The most fruitful recruitment
arena, however was the local PD exercise groups. It stands to reason that if
someone is motivated to attend exercise groups, they may also be motivated
to participate in a research study. Exercise is related to improved PD
symptomology. Therefore, another area for future research is the impact of
combined NFB and exercise, comparing groups who exercise with those who
do not.

x

Research design and practical considerations. Due to the number of sessions
and the time commitment required by participants, the single subject design
is more practical than an experimental design using a control group. Asking
people with a significant health condition such as PD to attend 20 or more
NFB sessions, knowing half would receive placebo treatment, is requesting a
great deal of research participants. For the pilot study, there was no sham
condition, and the control person was offered and accepted the same number
of NFB sessions the treatment groups received after data collection was
completed. For a placebo (sham) condition, however, this means those in the
control group have to attend twice as many sessions as the experimental
group (sham sessions and then the actual NFB sessions following the end of
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the study). This is a challenge for anyone with a chronic condition, and other
factors, such as bad weather, add to the respondent burden this creates.
x

PD staging and sample selection. The single subject design may minimize the
effect of the sample including participants at different stages of PD. That is,
each participant serves as her or his own control; therefore, results are based
on differences between pre- and post-response for each person. However, as
PD advances, the number, variability, and interactions of symptoms also
progress, and this may affect results. With mid-stage and later stages of PD, it
becomes increasingly difficult to isolate the effects of the intervention. One
way to determine sample comparison would be to stratify the sample based
on the pretest cognition (WHODAS) or tremor (PQ) pretest scores. In this
way, people with similar levels of disability or affectedness from PD at pretest could be compared.

x

Under- and over-reporting. Because PD is slowly progressive, patients and
families are able to adapt to changes in activity levels over time, as well as
make adaptations that may be required at home, which means they may not
be acutely aware of the impact of these changes. This gradual
accommodation may result in an under-reporting of symptoms at pretest.
For example, at pre-test, one participant began to write “none” in response to
the WHODAS item “How much difficulty do you have moving around inside
your home?” His wife observed his answer and pointed out that he could no
longer go up or down stairs at home and that they had made many personal
and structural accommodations for PD. In fact, they were selling their current
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home and building a new one because of his PD. It was accurate that he could
move around his current home without difficulty but this was due to the
accommodations they had made. Conversely, during the intervention,
participants are perhaps more focused on their symptoms (and whether or
not they are improving) and therefore, may be more likely to over-report
symptoms at post-test and followup. Measures that eliminate this type of
ambiguity would more accurately capture any changes resulting from the
intervention. Though the WHODAS has been well-tested and validated
internationally, it may not always capture the impact of disease for this
population. Another way to offset any under- or over-reporting would be to
include reporting by family members (e.g., spouse, adult child) in order to
document differences noted by more than one person.
x

Number of NFB sessions. In order to demonstrate significant changes on
broad measures of disability, more than 20 sessions, or in other words, a
higher dosing of neurofeedback, is likely required. It may also take more
sessions to up-train SMR and beta, which were the only EEG bands that did
not show improvement. SMR and beta are associated with active attention
and being alert yet relaxed. ADHD is one condition that has been wellresearched using NFB, and 40 sessions are often used in protocols for ADHD
(e.g., Lofthouse, et al., 2011). While comorbidity may exist with any
condition, ADHD is non-degenerative and therefore, any comorbidity may be
less impactful on outcome measures than with a degenerative condition, such
as PD. Also, ADHD research typically involves children and youth, and with
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degenerative conditions, the study populations are typically older and more
likely to have comorbid conditions and life events that impact symptoms that
are unrelated to the intervention. Resting tremor may also have interfered
with training for some participants, and in these cases, more sessions may
also be required to demonstrate change.

Clinical Recommendations
Specific clinical recommendations include the following:
x

Protocols. Based on the qualitative reports, most participants noticed
improvement in the cognitive and motor issues addressed by the protocols,
and these issues showed improvement on quantitative measures for some
participants, especially those diagnosed longer ago. Based on the reported
importance of planning in the focus group, and the nearly universal impact of
tremor in PD, retaining a multiple symptom focus on these conditions seems
advised.

x

Session length. Three of the 7 participants (C, E, and F) reported short-lived
fatigue following sessions, and one participant noted mild headache. A more
gradual approach to session length may have the advantage of creating less
fatigue in the early sessions by allowing participants to slowly become
accustomed to the training. For example, for a 20 session protocol, the first 5
sessions could be 12 minutes in length for each protocol, the next 10
sessions, 20 minutes each, and the final 5 sessions, 30 minutes. This would
result in a comparable total hours of training as the current study (13.6
hours, compared to 13.3 for the current study). Also, if fatigue is less of a
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problem at posttest, this may allow for the capture of a more accurate result
based on the training, without the influence of transient fatigue due to NFB
training. Another possibility is home-training, in which the subject (or family
member) is trained to use NFB equipment at home for a given number of
sessions. This would create issues of fidelity to procedures for a research
study but may work well for clinical use.
More generally, in terms of clinical practice, this study adds to the evidence that NFB
can be a useful therapy in alleviating motor symptoms of PD, particularly for those who are
further away from diagnosis and as symptoms progress. NFB may be especially useful for
symptoms not typically addressed by medication, such as cognitive problems. The high cost
and long course of the disease, high prevalence of significant comorbidities, and
importance of symptom delay, including delaying medication initiation and increases, make
NFB an important therapy in defending against disease progression.
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Appendix B. Focus Group Recruitment Script
My name is JoAnne McFarland O'Rourke, and I am leading a study examining the effect of
neurofeedback on the symptoms of Parkinson’s Disease. I am the Director of Research in
the College of Health and Human Services at WMU and I have a neurofeedback and
counseling private practice. I am also a PhD student at WMU and plan to use the data that I
collect for this study for my dissertation.
I am recruiting between 6-12 people to be part of a focus group discussion about the
symptoms people experience as a result of Parkinson’s Disease. If you agree to be part of
the focus group, you will be asked to participate in a single meeting. The discussion topics
will include the aspects of Parkinson’s that you find particularly challenging and those that
may be present but less challenging to you.
You will need to arrive an hour early and the discussion will last about 2 hours. Therefore,
your time commitment will be 3 hours. The meeting will be held during business hours,
Monday to Friday starting between 9-11 AM and concluding between 12-2 PM. The
meeting will be held on the WMU East Campus (Oakland Drive).
We will videotape the discussion to ensure that responses are accurately captured.
Therefore, you must agree to be videotaped to participate in the focus group.
I would like to hold the group in the next month and will try to arrange a time that is most
convenient for the participants. If you are interested in learning more, please let me know. I
will stay after the meeting to talk with you or you may call me at (269) 387-8445. I can also
provide you with my business card.
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Appendix C. Focus Group Informed Consent Document
CONSENT TO PARTICIPATE IN A RESEARCH STUDY
PRIORITIZING PARKINSON’S DISEASE SYMPTOMS
FOCUS GROUP
Introduction and Purpose
You are invited to be part of a research project. The purpose of the project is
finding ways to decrease symptoms of Parkinson Disease (PD).
There are two parts to the project:
1. A focus group with Parkinson Disease patients about the symptoms that
patients find problematic and
2. An intervention study that will test two different neurofeedback
protocols.
This consent is for the focus group study (1) only.
The Michigan Parkinson Foundation (MPF) is funding the study. JoAnne
McFarland O’Rourke, LMSW, Director of Research, College of Health and
Human Services (CHHS), Western Michigan University (WMU), is the student
investigator who is conducting the study.
What participation involves
If you agree to be part of the focus group, you will be asked to participate in
one meeting. The meeting will be held at the College of Health and Human
Services building on the WMU East Campus (Oakland Drive).
Between 6-12 people will meet for about 2 hours to discuss the symptoms
they experience. You will need to arrive one hour early to turn in or sign this
informed consent document and to have any questions you have answered.
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The discussion topics will include the aspects of PD that you find particularly
challenging and those that may be present but less challenging to you. You will
need to arrive an hour early; therefore, your time commitment will be 3 hours.
Ms. McFarland O’Rourke will help guide the discussion. Her role includes
managing the discussion and making sure everyone has a chance to respond.
We will videotape the discussion to ensure that responses are accurately
captured. You must agree to be videotaped to participate in the focus group.
Subject Recruitment and Participant Selection
Persons eligible to participate in the study are those:
With a diagnosis of Parkinson’s Disease
Without significant psychiatric illness
Without a significant physical health problem other than PD
Study participants were recruited via flyers from the Bronson Neuroscience
Center, Bronson Healthcare Midwest Neurology, and the Kalamazoo Area
Parkinson Support Group, which meets at the Bronson Athletic Club.
People were invited to the group on a first-come basis, and you were among
this group.
Voluntary nature of the study
Participating in this study is completely voluntary. Even if you decide to
participate now, you may change your mind and stop at any time. You may
choose not to answer a focus group question for any reason. Also, you may
stop participating in the study at anytime for any reason. There are no adverse
consequences for deciding to stop participating.
Participating in the focus group will not affect the likelihood that you will be
invited to participate in the next part of the study.
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Location
The focus group will take place in a conference room on the third floor of the
WMU College of Health and Human Services (Room 3267). The building is
located at 1101 Cass Street, Kalamazoo MI 49008, at the intersection of
Oakland Drive and Oliver Street. The building is fully handicap accessible
(elevators, restrooms, flooring).
Free parking will be provided and directions will be sent.
Risks and discomforts
Answering questions or talking with others about illness can be difficult. You
may choose not to answer any discussion question. Also, you can stop your
participation in the focus group at any time. You will be provided with a list of
local agencies that can provide you with additional information or support if
you are interested.
All focus group members will be asked to respect the privacy of other group
members. You may tell others that you were in a focus group and the general
topic of the discussion. However, actual names, stories, and any other
identifying information of other participants should not be shared. While
unlikely, there is a chance that another member of the focus group could
reveal something about you or your family that they learned in the discussion.
Benefits
There are no direct benefits from participating in this research. However,
some people find sharing their stories to be a valuable experience. Also, the
ultimate goal of the study is to find ways to address symptoms associated with
PD. Therefore, your participation may help in this effort.
Compensation and Cost
You will receive a $20 gift card for participating in the focus group session.
Parking will be free-of-charge but you will need to arrange and pay for your
own travel to the College of Health and Human Services. If someone drives
you to the focus group, they will be asked to wait in the building atrium.
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Confidentiality and data use
The data from the study are planned for publication but will not include any
information that would identify you. To keep your information safe, the
videotape of the focus group will be stored on a secure computer at CHHS.
Later, a transcript of the discussion will be created. Study data will be entered
on a computer that is password-protected and accessible only to Ms.
O’Rourke. To further protect confidentiality, your real name will not be used
in the written copy of the discussion. The videotape will be destroyed after 3
years.
There are some reasons why people other than the researchers may need to
see information you provided as part of the study. This includes organizations
responsible for making sure the research is done safely and properly. These
organizations may include Western Michigan University or government
research offices. If you reveal something that makes us believe that you or
others have been or may be physically harmed, we are obligated to report that
information to the appropriate agencies.
When referring to family members, friends, or others, please use the person’s
relationship to you (e.g., “my son”) and not the person’s name (e.g., “Chris”).
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Contact information
If you have questions about this research, including questions about the
scheduling of the focus group or your payment for participating, you may
contact:
JoAnne McFarland O'Rourke, Director of Research
College of Health and Human Services
1903 W. Michigan Avenue
Kalamazoo MI 49008-5243
(269) 387-8445 Phone
(269) 387-7435 Fax
joanne.orourke@wmich.edu
If you have questions about your rights as a research participant, or wish to
obtain information, ask questions or discuss any concerns about this study
with someone other than the researcher, please contact:
Health Sciences Institutional Review Board, Chair
Western Michigan University
251 W. Walwood Hall
Kalamazoo, MI 49008-5456 USA
(269) 387-8293 Phone
(269) 387-8276 Fax
research-compliance@wmich.edu
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Consent
The WMU Human Subjects Institutional Review Board (HSIRB) has approved
this consent document. The approval is valid for one year. The approval
period is indicated by the stamped date and signature of the board chair in the
upper right corner. Do not participate in this study if the stamped date is older
than one year.
By signing this document, you are agreeing to be in the focus group. You will
be given a copy of this document upon request and one copy will be kept with
the study records. Be sure that your questions about the study have been
answered and that you understand what you are being asked to do. Please
contact Ms. O’Rourke if you think of a question later.
I have read this document. I have had the opportunity to ask questions
about it. Any questions that I have asked have been answered to my
satisfaction. I consent voluntarily to participate in this research. As part
of my consent, I agree to be videotaped and not to share names, stories,
or any other identifying information about others in the group.

__________________________________________________________
Name (printed)

___________________________________________________________

____________________

Signature

Date
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Appendix D. Focus Group Protocol
Overview and Guidelines
Thank you very much for agreeing to participate in today’s focus group. My name is JoAnne
McFarland O'Rourke, and I am leading a study examining the effect of neurofeedback on the
symptoms of Parkinson’s Disease. I am the Director of Research in the College of Health and
Human Services at WMU and I have a neurofeedback and counseling private practice. I am
also a PhD student at WMU and plan to use the data that I collect for this study for my
dissertation.
I would like to outline a few ground rules. First, we are video recording today’s group, and
as a backup, we are also audio recording. It will be very helpful if you can speak up, as well
as speak one at a time to help ensure that your comments come through on the recording.
Second, a few words about confidentiality: Please use only first names when addressing
each other, and when speaking about a family member or friend, please refer to that
person’s relationship to you and not her or his name. I ask that you respect the group’s
privacy by not repeating what others say here today.
In terms of the data I am collecting through this group, the information that each of you has
to share regarding your experience with Parkinson’s Disease is very important. However,
individual identities are not important. Therefore, no reports will ever link your name to
what you say or identify you in any way.
This group is intended to be a discussion among you, the participants, so please address
your responses to the entire group and feel free to respond to each other’s comments. My
role is to ask questions, listen, and when needed, clarify responses and ensure that
everyone has a chance to speak. I would like to hear from everyone and to hear your
response to questions, even if they are different than everyone else’s. The group may form
a agreement on some questions, and on other questions, there may be a difference of
opinion – both of these are OK.
I will ask each question and then we will pause for about a minute or two to allow you to
gather your thoughts before we start the discussion. The notepads and pencils in front of
you are for writing down ideas during the pause before each question or at other times, as
you wish.
At about the halfway point we will stop for a 10-15 minute break and then pick up where
we left off. If anyone needs to take a break before the halfway point, just let me know and
we will take a break then. [POINT OUT WHERE RESTROOMS ARE LOCATED]. If you have
not done so already, please silence your cell phones.
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Let’s begin by having each of you introduce yourself, including your first name and
anything else that you would like to add.
[INTRODUCTIONS]
Thank you. Do you have any questions before we begin with the focus group?
[RESPOND TO QUESTIONS]
INTRODUCTION
The key objective of this focus group is to gain insight about how Parkinson’s Disease
patients would prioritize symptoms of the disease in terms of how much they interfere
with quality of life.
Question 1
My first question has to do with how Parkinson’s has affected you lately. When you think
about your ability to enjoy life over the past month, in terms of Parkinson’s, what has
gotten in the way?
[PAUSE FOR A MINUTE AND THEN INVITE RESPONSES]
PROBES:
x
x
x
x

WHAT ARE THE FIRST THINGS YOU THINK OF?
WHAT SEEMS MOST SIGNIFICANT?
SOME THINGS MIGHT HAVE TO DO WITH GETTING AROUND, INTERACTING WITH
OTHER PEOPLE, HOW YOU FEEL PHYSICALLY, HOW YOU FEEL EMOTIONALLY, OR
YOUR ENERGY LEVEL.
SEE SYMPTOM LIST IF NEEDED.

Question 2
Thank you. Now, thinking about the last 6 months to a year, when you think about your
ability to enjoy life over this longer timeframe, in terms of Parkinson’s, what are the issues
that have gotten in the way?
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PROBES:
x
x
x
x

ARE THERE THINGS YOU WOULD ADD TO THE LIST FROM QUESTION 1?
WHAT HAVE BEEN SOME OTHER AREAS OF CONCERN?
ARE THERE ACTIVITIES THAT ONLY HAPPEN 1-2 TIMES A YEAR, SUCH AS CHRISTMAS
OR BIRTHDAY PARTIES, THAT HAVE CREATED SPECIAL CHALLENGES FOR YOU?
SEE SYMPTOM LIST IF NEEDED

BREAK FOR 10-15 MINUTES
Question 3
Thank you very much. Some changes to functioning may impact you daily but you find that
they are manageable, either through medication or ways that you have learned to adapt.
Other changes may not affect you daily but overall, they impact you a lot in terms of
affecting your ability to enjoy things that are important to you.
My next question is, how impactful are the changes to functioning that you described in the
two first questions in terms of your ability to enjoy life?
PROBES:
HOW HAS YOUR DIAGNOSIS AFFECTED YOU THE MOST?
ENSURE ALL ISSUES MENTIONED IN QUESTION 1 AND 2 ARE DISCUSSED
Closing
Thank you. This concludes the questions for the group. Please accept my thanks for
participating in today’s group. I appreciate your time and candor, and want to assure you
that your responses will be very helpful.
[Distribute gift cards and wrap-up]
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Definitions
QOL:
Both positive and negative aspects of life.
Physical and mental health perceptions and their correlates—including health risks and
conditions, functional status, social support, and socioeconomic status.
Symptoms / changes list
Moving
Balance
Tripping, falling
Walking, getting around, walking speed
Executive function and cognition
Driving
Balancing checkbook
Making decisions
Thought process
Multi-tasking
Communication
Talking
Clarity
Expression
Word-finding
Sound, softness
Maintaining thought process
Other physical symptoms
Swallowing
Tremors/shaking
Mood
Low mood
Depression
Motivation
Enthusiasm
Apathy
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Anxiety
Worry
Fear
Concern
Apprehension
Life changes
Relationships, impact
Job, volunteering
Medication
Interactions/side effects
Medication ineffective

111

112

Appendix E. World Health Organization Disability Assessment
Scale
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Appendix F. UPDRS Patient Questionnaire
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Appendix G. Intervention Study Informed Consent Document
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